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Hong Liu

Advisory Professor: Yang Xia, M.D., Ph.D.

Adenosine is a ubiquitous nucleoside in almost all the cells throughout our
bodies. It is highly induced particularly under hypoxia or energy depletion
conditions. Adenosine functions as a critical ligand, after binding to membraneassociated adenosine receptors, adenosine initiates a downstream signaling
cascade and subsequently contributes to functions of nervous system, immune
response, vascular function and even metabolism.

Hypoxia is a condition with limited O2 availability in the whole body or a region
of the body. It is a major consequence of many respiratory and cardiovascular
diseases, as well as for people living and working at high altitudes or other low O2
conditions. Without intervention, it can progress to pulmonary and cerebral edema,
stroke, cardiovascular dysfunction and death. Although hypoxia-induced tissue
damage is a serious condition with high morbidity and mortality, safe and effective
mechanism-based therapies are limited.

The erythrocyte is the most abundant circulating cell type and functions as the
only cell-type responsible for O2 availability in peripheral tissues. Its fundamental

v

function, O2 release capacity and O2 delivery capacity, is determined by
hemoglobin-O2 binding affinity and cell number, respectively.

Although adenosine signaling is beneficial under stress conditions in various
organs and tissues via activation of different adenosine receptors, its significance
and functional role in the erythroid lineage, particularly under stress conditions, are
still unclear.

My dissertation employing multi-disciplinary approaches including human
studies, novel genetic tools, and sophisticated pharmacological studies coupled
with metabolomic profiling shows for the first time that 1) CD73-dependent
elevation of plasma adenosine signaling via erythrocyte specific ADORA2B
coupled with AMP-activated protein kinase is a key mechanism for hypoxia
adaptation via induction of 2,3-BPG production with O2 release to counteract
severe hypoxia. 2) Adenosine signaling via erythroid ADORA2B is a previously
unrecognized purinergic signaling responsible for stress erythropoiesis by
regulation of erythroid commitment in a hypoxia-inducible factor 1-alpha dependent
manner.

Thus, my research has identified that adenosine signaling functions as a novel
molecular mechanism involved in the regulation of erythrocyte O2 release capacity
and O2 delivery capacity, providing therapeutic possibilities to enhance O2
availability and prevent stress-induced tissue damage and inflammation, a strong
foundation for future clinical trials to treat diseases associated with hypoxia or
hematology disorders provided by my doctoral work.
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Chapter 1: Background introduction

This chapter is based on the review paper “Hong Liu, Yang Xia. Beneficial and
detrimental role of adenosine signaling in diseases and therapy. Journal of Applied
Physiology Published 27 August 2015 DOI: 10.1152/japplphysiol.00350.2015”

Permission of the copyright by the American Physiological Society

Theses and dissertations. APS permits whole published articles to be
reproduced without charge in dissertations and posted to thesis
repositories. Full citation is required.
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1.1 Background of adenosine signaling
1.1.1 Metabolism of adenosine
Adenosine is ubiquitously produced in almost all of the cells in our bodies under
physiological condition and further produced under hypoxia or energy depletion
condition. As a building block and a critical intermediate metabolite of nucleic acids,
adenosine is a key signaling molecule that orchestrates the cellular response to
hypoxia, energy depletion and tissue damage by activation of its G-protein coupled
receptors (GPCR) on multiple cell types1. Under normal physiological conditions, both
extracellular and intracellular adenosine levels are in the nanomolar range. However,
under stress conditions, ATP is released from injured cells such as endothelial cells2
and neutrophils3 via transmembrane protein channel including pannexins4 or
connexins3, 4, and subsequently dephosphorylated to extracellular adenosine by ectonucleotidases including CD39, which converts ATP to ADP/AMP and CD73, which
converts AMP to adenosine5, 6. Under pathological conditions, extracellular adenosine
concentrations can reach the millimolar range7. Generation of extracellular adenosine
through these pathways is the major source of extracellular adenosine production
under hypoxia-induced injury. In addition, extracellular adenosine is regulated by
adenosine deaminase (ADA), which is responsible for the degradation of extracellular
adenosine into inosine8. Moreover, extracellular adenosine signaling is terminated by
equilibrative nucleoside transporters (ENTs), which are involved in the cellular uptake
of adenosine. Once inside the cell, adenosine is metabolized by two enzymes,
adenosine kinase (ADK) and adenosine deaminase (ADA). ADA catalyzes the
irreversible conversion of adenosine to inosine. ADK phosphorylates adenosine to
2

AMP, and is critical for regulating intracellular levels of adenosine and maintaining
intracellular levels of adenine nucleotides7. Intracellular adenosine homeostasis is also
maintained by bi-directional equilibrative nucleoside transporters (ENTs) on the plasma
membrane, through facilitated diffusion of adenosine in the direction of the
concentration gradient (Figure 1)9.

3

Figure. 1. Metabolism of adenosine signaling.
Cells release ATP through connexins or pannexins channels under hypoxia and other
stress conditions. The accumulation of extracellular ATP is dephosphorylated to
adenosine (A) by 2 ecto-nucleotidases including CD39 and CD73. Adenosine can
further be metabolized by adenosine deaminase (ADA) to inosine or functions as a
signaling molecule by activation of its adenosine receptors (AR) on multiple cell types.
Once uptake by equilibrative nucleoside transporters (ENTs), adenosine is further
metabolized by adenosine kinase (ADK) to AMP, adenosine deaminase (ADA) to
inosine, or S-adenosylhomocytesine hydrolase (SAHH) to adenosylhomocysteine
(AdoHcy).
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1.1.2. Adenosine signaling via adenosine receptors
Increases in extracellular adenosine in turn elicit various responses on target cells
by engaging cell surface adenosine receptors both in physiological and pathological
conditions10. As GPCRs, adenosine receptors all have a single polypeptide chain which
is a structural motif forming seven transmembrane helices. There are four adenosine
receptors (ADORA1, ADORA2A, ADORA2B, and ADORA3), and each receptor has a
cellular or tissue specific distribution and distinct affinity for adenosine 11. ADORA1,
ADORA2A, and ADORA3 have a high affinity to extracellular adenosine, while
ADORA2B has the lowest affinity to extracellular adenosine. Thus, ADORA2B is
normally activated under pathological conditions due to excess accumulation of
extracellular adenosine. A1 and A3 adenosine receptors are coupled to adenylyl
cyclase by the inhibitory G-protein subunit (Gαi) and thereby can lower intracellular
levels of the second messenger cyclic adenosine monophosphate (cAMP). In contrast,
the A2A and A2B adenosine receptors are commonly coupled to adenylyl cyclase by
the stimulatory G-protein subunit (Gαs) and therefore can induce intracellular cAMP
levels. Therefore, signaling through adenosine receptors plays important roles in the
regulation of intracellular cAMP and thereby regulate multiple cellular functions
including vasodilation in endothelial cells, neurotransmitter release from neuronal cells,
neutrophil chemotaxis and vascular smooth muscle cell relaxation12, 13 (Figure 2). In
addition, other signaling molecules including phospholipase C (PLC), calcium, nitric
oxide (NO), reactive oxygen species (ROS), PI3K-AKT, extracellular signal-protein
kinase (ERK), and mitogen-activated protein kinases (MAPKs) are implicated
functioning downstream of adenosine receptors and subsequently regulating multiple
cellular functions. For example, activation of ADORA2A stimulates the PLC pathway
5

and adenylate cyclase pathway14. ADORA2A signaling is also engaged in modulation
of neutrophil function by regulating production of ROS 15,

16.

By modulation of NO

production via vascular endothelial cells, adenosine through ADORA2A receptor
functions as a potent vasodilator involved in tissue blood flow and cellular
homeostasis17,

18.

In addition, shear stress-mediated elevated adenosine activates

ADORA2B, subsequently contributes to endothelial NO synthase phosphorylation via
PI3K-AKT, and further generates NO19. Both pharmacological and genetic studies
show that adenosine ADORA2B induces inflammatory cytokine IL-6, and contributes
to the renal fibrosis20. The activation of ADORA3 triggers MAPK, and contributes to the
critical role of cell growth, survival and differentiation 21. Other studies report that
activation of ADORA3 modulates the proliferation of melanoma cells by regulation of
ERK pathway (Figure 2)22. Thus, activation of adenosine receptors are involved in
multiple cellular function via multiple downstream signaling cascade.
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Figure. 2. Adenosine receptor-mediated signaling pathways. Extracellular
adenosine functions as signaling molecule by engaging cell surface adenosine
receptors (ADORA1, ADORA2A, ADORA2B, and ADORA3). ADORA1 and ADORA3
adenosine receptors are coupled to adenylyl cyclase (AC) by the inhibitory G-protein
subunit (G i) and thereby can lower intracellular levels of the second messenger cyclic
adenosine monophosphate (cAMP). In contrast, the ADORA2A and ADORA2B
adenosine receptors can induce AC by the stimulatory G-protein subunit (G

s)

and

therefore can induce intracellular cAMP levels. Activation of both ADORA1 and
ADORA2B stimulates phosphatidylinositol 3-kinase (PI3K)/AKT pathway, and
activation of both ADORA2A and ADORA2B induces release of ROS, EETs, and PGI
2 . PKA, protein kinase A; PLC, phospholipase C; ROS, reactive oxygen species; EETs,
epoxyeicosatrienoic acids; PGI 2, prostacyclin; eNOS, endothelial NO synthase; NO,
nitric oxide; IL-6, interleukin 6; MAPK, mitogen-activated protein kinases; ERK,
extracellular signal-protein kinase.
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1.1.3. Adenosine signaling in physiological and pathological conditions
Adenosine is involved in numerous critical physiological processes via activation
of its adenosine receptors including modulation of nervous system, immune response,
vascular function and metabolism13,

23.

Adenosine-mediated biological function is

mainly dependent on activation of adenosine receptors, and responses of these cell
surface receptors are predominantly determined by adenosine concentrations. Since

function of adenosine signaling is through activation of A1, A2A or A3 adenosine
receptors, w

. In contrast, activation

of ADOAR2B requires a higher adenosine concentrations which generally exist under
pathophysiological conditions24. With the development and generation of various
adenosine receptors agonists or antagonists and four adenosine receptor knockout
mouse models, adenosine signaling has been demonstrated as an essential player
under pathophysiological conditions by modulation of inflammation, ischemic tissue
injury, fibrosis and tissue remodeling25-27.
1. 2. Beneficial role of adenosine signaling during acute stage
Recent studies indicate that extracellular adenosine functions as a signaling
molecule, which plays an essential role in adaptation to stress especially hypoxia 26, 28,
29.

Extracellular adenosine is induced during limited oxygen availability or acute injury,

and adenosine is critical for hypoxia adaptation, maintenance of cellular function and
protection of hypoxia-induced tissue injury. Under acute hypoxic conditions, adenosine
plays various beneficial role including vasodilatory effect, anti-vascular endothelial
leakage and anti-inflammatory response30-34.

8

1.2.1. Beneficial role in acute heart injury
Beneficial role of adenosine in acute stage was initially found in cardiovascular
system showing that adenosine functions as a potent vasodilator increasing blood flow
to coronary arteries 35. Later on, adenosine was implicated to play a generally protective
role in the heart by regulation of heart rate, coronary flow, contraction, inflammatory
control and tissue remodeling36. All four adenosine receptors are known to be involved
in coronary flow. Generally, adenosine exerts its cardiac electrophysiologic effects
mainly through the activation of ADORA1 that leads to a reduction in contraction rate37.
Adenosine A2A receptor is the major receptor subtype responsible for coronary blood
flow regulation in endothelial-dependent and -independent manner38, previous study
reported that adenosine increase coronary flow via vasodilation by promotion of
prostacyclin release39. Regadenoson (Lexiscan), a specific ADORA2A agonist, was
approved by FDA and utilized for diagnosis of myocardial perfusion imaging 40. In
addition, the Eltzschig group reported that CD73-mediated adenosine signaling via the
ADORA2B is important in cardioprotection by ischemic preconditioning. However,
Chen and colleagues reported that selective inhibition of adenosine A3 receptor
significantly attenuate pressure overload-induced left ventricular hypertrophy and
dysfunction41. These results suggest that selective CD73 agonists and ADORA2B
agonists are potential therapeutic possibilities for myocardial ischemia, and specific
ADORA3 antagonists may be a novel strategy to counteract pressure overload-induced
left ventricular hypertrophy and dysfunction41, 42.

1.2.2. Beneficial role in acute lung injury
9

Acute lung injury (ALI) is defined as pulmonary edema and severe hypoxia.
Multiple factors including pneumonia, aspiration or lung contusion, or indirect injury
such as sepsis, severe trauma, blood transfusion cause ALI. Approximately 200,000
patients develop ALI in the US annually. However, due to the lack of understanding the
molecular mechanism involved in the development and progression of ALI, no effective
therapeutic options are available. Several groups reported that adenosine serves
beneficial functions on features of ALI such as enhancing alveolar-capillary barrier
function and dampening inflammation, and substantially protects against ALI resulting
from hypoxia or ischemia43, 44. Follow-up genetic and pharmacological studies reported
that the adenosine mediated beneficial role in ALI is via ADORA2B in a CD73
dependent manner45,

46.

Therefore, these studies provide potential development of

adenosine-based therapies for the treatment of ALI44, 47, 48.
1.2.3. Beneficial role in acute kidney injury
Acute kidney injury (AKI), characterized as the rapid dysfunction of kidney, is
currently the leading cause of mortality and morbidity in hospitalized patients, therefore
effective therapeutic strategies are urgently needed. Among multiple factors, renal
ischemia is the most common cause of AKI. Previous studies indicated that all four
adenosine receptors are expressed in the kidney and are involved in progression of
AKI49. Particularly, several studies reported adenosine A1 receptor signaling protects
the kidney from ischemia-reperfusion injury50-53. Linder’s group showed that adenosine
A2A receptor signaling prevents ischemia-induced injury via modulation of
inflammatory cells54, 55. In addition, pharmacological and genetic studies demonstrate
that adenosine A2B receptor signaling is involved in renal protection during
10

preconditioning56. In contrast, activation of the ADORA3 is implicated as detrimental
during renal ischemia52.
1.2.4. Beneficial role in brain
As an important signaling molecule, adenosine coupling with its specific receptor
functions as an upstream neuromodulator of neurotransmitters involved in the
homeostasis and modulation of multiple brain function57, 58. For example, previous
studies demonstrated that adenosine is present in the extracellular fluid in brain, its
level is dramatically induced in the condition of hypoxia or ischemia, and subsequently
plays critical effects through activation of its specific receptors. Although all four
adenosine receptors are expressed in the mouse forebrain, ADORA1 and ADORA2A
have the highest abundance in the brain. Thus, those two adenosine receptors play
critical roles in the brain function, while ADORA2B and ADORA3 have relatively modest
impact on brain function59,

60.

It is found that ADORA1 is located presynaptically,

postsynaptically and nonsynaptically in brain59, and mainly underlies effect of
adenosine in neuronal circuits by selectively depressing excitatory synaptic
transmission61. Both pharmacological evidence and genetic ADORA1 knockout mouse
studies demonstrate neuro-protective role of ADORA1 in ischemia/hypoxia models of
brain injury62. In contrast, ADORA2A are demonstrated to have a widespread
distribution in the brain59. Several lines of evidence suggest that adenosine signaling
via ADORA2A is neuroprotective under different pathological conditions including
hypoxia63, ischemia64,

65,

and hypoglycemia66. Mechanistic studies demonstrated

adenosine-mediated protective effect in the brain is through ADORA2A by controlling
brain vascular function through endothelial cells. For instance, ADORA2A plays a
beneficial role in preventing brain ischemia by induction of cerebral blood flow (CBF) in
11

multiple conditions

including energy failure, tissue acidosis, imbalance of ion

homeostasis and cytotoxic edema67, 68. In addition, Winn and colleagues found that the
capacity to modulate CBF in response to hypotension was significantly impaired in
ADORA2A knockout mice, and treatment with extracellular adenosine transporter
inhibitor, dipyridamole, significantly increases circulating adenosine concentrations and
subsequently improves CBF in mice, indicating the importance of adenosine
ADORA2A in physiologic vascular regulation of

CBF69. Furthermore, both

pharmacological and genetic studies demonstrated that ADORA2A stimulates
proliferation of Schwann cells70. Additional studies showed that specific activation of
other adenosine receptors contributes to the adenosine-mediated neuroprotective
effects as well. For instance, preclinical study showed that A3 specific agonist prevents
ischemic brain injury through suppression of apoptosis in wild type mice, but not in the
ADORA3-deficient mice71. Clinical human studies demonstrated that adenosine plays
a role of vasodilatation in the cerebral circulation which can be applied for investigation
of cerebrovascular perfusion capacity in patients with carotid occlusive disease 72.
Overall, adenosine singling via its specific receptors plays an important role in brain
function and modulating adenosine signaling is likely an effective treatment for brain
ischemic injury and damage. 2.5.
1.2.5 Beneficial role in multiple organ damage at acute stage
Adenosine was reported to be beneficial under stress conditions in various organs
and tissues through different adenosine receptors

73-76.

Several studies report that

adenosine play a otoprotective role in the auditory system to counteract intense noise
exposure

77, 78.

Cronstein’s group demonstrate that adenosine A2A signaling plays

beneficial role in skin by promoting would healing and angiogenesis
12

76.

Colgan and

colleagues used pharmacologic and genetic approaches to show that adenosine
signaling via the A2B receptor attenuates tissue injury and inflammation in mucosal
organs during intestinal ischemia and colitis79-82. Gnad et al. demonstrate that
adenosine stimulate brown adipose tissue thermogenesis via ADORA2A, and
ADORA2A selective agonist prevent high fat diet-induced obesity in mice

83.

Linden’s

group reported that elevated adenosine protects the liver from ischemic reperfusion
injury via ADORA2A signaling

84.

In addition, they show that ADORA2A signaling

prevents pulmonary inflammation in a sickle cell disease (SCD) mouse model by
reducing invariant natural killer cells. Therefore, FDA-approved ADOA2A specific
agonist, regadenoson, is currently utilized to conduct a clinical trial in the treatment of
patients with SCD 85, 86.
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Table 1. The beneficial role of adenosine signaling in acute conditions
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1.3 Adenosine signaling in erythrocyte
Although erythrocyte is the most abundant cell type in the body, the role of
adenosine in erythrocyte has not been recognized. Recently, our laboratory first
reported the functional role of adenosine signaling in erythrocyte in physiology condition.
Erythrocyte is the major source of O2 to each organ and tissue, and its O2 carrying
capacity is mainly regulated by hemoglobin- binding O2 affinity. Previous studies
showed that hemoglobin- binding O2 affinity is tightly regulated by the 2,3bisphosphoglycerate (2,3-BPG), which is an important erythroid specific metabolite
existing in the glycolytic pathway. However, how the level of 2,3-BPG was regulated is
still unclear. By using genetic mouse models, pharmacological tools coupled with
human evident, we revealed an important role of adenosine signaling in the regulation
of erythrocyte 2,3-BPG. In details, we showed that adenosine specific analogue, 5’-Nethylcarboxamidoadenosine (NECA), can directly induces 2,3-BPG levels in cultured
mouse mature RBCs. Furthermore, by using four adenosine receptor deficient mice
models, we showed that NECA can induce 2,3-BPG level in cultured RBCs isolated
from WT, Adora1, Adora2a and Adora3 mice, but not in the Adora2b mice, which
indicates that adenosine signaling-induced erythrocyte 2,3-BPG in RBC is via
ADORA2B. However, what is the significance and functional role of adenosine
signaling-mediated regulation of RBC 2,3-BPG particularly in stress condition, and how
2,3-BPG was regulated by adenosine ADORA2B in RBC is still unclear. These
important questions will be further addressed in the Chapter 2 of my dissertation.
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1.4 High altitude hypoxia
High altitude hypoxia is a condition in which the O2 availability is limited,
therefore O2 delivery from circulation to peripheral tissues is limited. This directly
causes poor exercise performance, even poor walking performance, and it can
have substantial impact on overall well-being and cognitive function. Without
intervention, high altitude hypoxia induces pulmonary edema, vascular damage
and interstitial fibrosis and death. Thus, improving O 2 delivery at the tissue level
has the potential to improve peripheral oxygen delivery and thereby raise exercise
performance and reverse cognitive deficits caused by hypoxemia. While the
relevance of improving O2 delivery has clear impact on military veterans with
hypoxemia secondary to chronic respiratory diseases, high altitude residence can
cause similar levels of hypoxemia. Current strategies to counteract hypoxia are
limited due to a lack of fundamental understanding of the molecular mechanisms
underlying adaptation to hypoxia. The erythrocyte is the most abundant cell type
in the circulation and is responsible for delivery of O2 to peripheral tissues. To
function effectively in O2 uptake, transport and delivery, erythrocytes tightly
dependent on sophisticated regulation of Hb-O2 affinity by endogenous allosteric
modulators. One of the best known allosteric modulators is (2,3-BPG), a metabolic
byproduct of glycolysis synthesized primarily in erythrocytes for the purpose of
regulating Hb-O2 affinity87. It has been known for more than four decades that when
humans ascend to high altitude the concentration of 2,3-BPG in erythrocytes
increases significantly and its elevation is correlated with an increased capacity of
O2 release from hemoglobin88. However, the molecular basis underlying altitude
16

hypoxia mediated induction of erythrocyte 2,3-BPG remains unknown and the
functional role of elevated erythrocyte 2,3-BPG in high altitude adaptation is
unclear.
1.5 Erythropoiesis and stress erythropoiesis
Erythropoiesis is an dynamic process to synthesize new erythrocyte, the only
cell-type responsible for delivering O2 to peripheral tissues in our body. Basically,
it can be divided into two types of erythropoiesis including primitive erythropoiesis
and definitive erythropoiesis. Primitive erythropoiesis is occurred in the fetal life,
which included 3 stages based on the duration of pregnancy. The first 2 months
called mesoblastic stage which was occurred in yolk sac. The second stagehepatic stage-was mainly happened in liver, spleen and lymphoid organs. The last
stage-myeloid stage-was occurred in red bone marrow. Definitive erythropoiesis is
the predominant one in adults, and mainly occurred in bone marrow. Normally, 2.4
million new erythrycotes per second are produced within bone marrow (BM) from
erythroid progenitors to enucleated reticulocytes and eventually mature
erythrocytes with a 120 day life span in the peripheral circulation. Basal
erythropoiesis can be further induced, known as stress erythropoiesis, in response
to high altitude, blood loss, infection, BM suppression and anemia to produce more
circulating reticulocytes and erythrocytes to counteract insufficient tissue
oxygenation1,2. Failure to stimulate effective erythropoiesis, results in hypoxia
which can progress to pulmonary edema, stroke, cardiovascular damage, multiorgan injury and death3-6. Thus, stress-induced erythropoiesis is an important
adaptive response for survival under hypoxic conditions. Erythropoiesis is an
17

·
extremely dynamic process finely regulated
by cytokines, hormones, growth

factors, among others at transcriptional and translational levels1,2. Stress-induced
-

erythropoiesis is defined as astimulated basal erythropoiesis with expansion of
the erythroid progenitor pool, resulting in reticulocytosis and splenomegaly. Stress
erythropoiesis is frequently induced by insufficient tissue oxygenation including
high altitude, blood loss, infection, myeloablation, and anemia. Inability to adapt to
hypoxia associated with these conditions can result in multi-tissue damage, stroke,
cardiovascular dysfunction and even death3 6. Thus, stress erythropoiesis is an
important hypoxic adaptive response for survival. Stress erythropoiesis has been
long speculated to be linked with increased metabolic requirements 7, The energy
metabolism of major nutrient including glucose, glutamine and fatty acids is
important for the survival, proliferation and differentiation to adapt to physiological
and pathological stress conditions. With the development of innovative
metabolomic profiling and state of art isotopically labelled metabolic flux
approaches8, glucose and glutamine metabolism are essential for stress
erythropoiesis7· 9 .
1.6 Sickle cell disease
Sickle cell disease is an inherited genetic blood disorder with high mortality
and morbidity that results from a single mutation in hemoglobin, the protein that
carries oxygen in red blood cells throughout our bodies. Although this disease was
discovered more than a century ago, we still lack effective mechanism-based
therapies. The mutant hemoglobin causes the red blood cells to acquire an unusual
sickle shape that hinders movement through blood vessels. The clumps of sickled
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cells block blood flow resulting in pain, serious infections, and organ damage. Our
laboratory has discovered a process that contributes to enhanced red blood cell
sickling, inflammation and progression of the disease and has identified a
mechanism-based therapeutic approach to inhibit this process.
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Chapter 2 Role of adenosine signaling in mature erythrocyte
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2.1 Introduction

High-altitude hypoxia is a challenging condition due to limited O2 supply. The
ability to adjust to high-altitude hypoxia varies considerably among individuals.
Failure to adapt to high-altitude hypoxia is associated with poor exercise
performance, severe headache, dizziness and vomiting. Without intervention, it
can progress to pulmonary and cerebral edema, stroke, cardiovascular dysfunction
and death89-91. Current strategies to counteract hypoxia are limited due to a lack of
fundamental understanding of the molecular mechanisms underlying adaptation to
hypoxia.
The erythrocyte is the most abundant circulating cell type and responsible for
delivery of O2 to peripheral tissues. To function effectively in O2 uptake, transport
and delivery, erythrocytes rely on sophisticated regulation of Hb-O2 affinity by
endogenous allosteric modulators. One of the best known allosteric modulators is
2,3-bisphosphoglycerate

(2,3-BPG),

a

metabolic

byproduct

of

glycolysis

synthesized primarily in erythrocytes for the purpose of regulating Hb-O2 affinity87.
It has been known for more than four decades that when humans ascend to high
altitude the concentration of 2,3-BPG in erythrocytes increases significantly and its
elevation is correlated with an increased capacity of O2 release from hemoglobin88.
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However, the molecular basis underlying altitude hypoxia mediated induction of
erythrocyte 2,3-BPG

remains unknown and the functional role of elevated

erythrocyte 2,3-BPG in high altitude adaptation is unclear.
To identify metabolic alterations of erythrocytes in response to hypoxia, we
conducted nonbiased high throughput metabolomic profiling of erythrocytes from
humans at sea level and at high altitude. Our results confirmed early studies that
erythrocyte 2,3-BPG levels are significantly elevated in response to high altitude,
but also led us to discover that circulating adenosine levels and activity of soluble
CD73 (sCD73), a key enzyme to generate extracellular adenosine, were
significantly enhanced in 21 lowland volunteers within two hours of arrival at 5260
m and continued to increase with time at this elevation. Significantly, hypoxiainduced elevated plasma adenosine level is correlated with erythrocyte 2,3-BPG
and O2 releasing capacity in human subjects. In vivo genetic mouse studies
coupled with in vitro both human and mouse studies demonstrated that increased
extracellular adenosine signaling via erythrocyte specific ADORA2B, led to the
sequential activation of AMPK and 2,3-BPG mutase, resulting in increased 2,3BPG production and enhanced O2 release capacity to peripheral tissues. Thus, our
findings highlight the importance of this newly identified erythrocyte adenosine
23

signaling pathway via AMPK in human adaptation to high altitude and identify
several attractive targets to counteract hypoxia in humans.
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2.2 Materials and Methods
2.2.1 Human Subjects
This study was conducted as part of the Altitudeomics project examining the
integrative physiology of human responses to hypoxia92. In brief, all procedures
conformed to the Declaration of Helsinki nd were approved by the Universities of
Colorado and Oregon Institutional Review Boards and the US Department of
Defense Human Research Protection office. After written informed consent,
recreationally active sea-level habitants participated in the adenosine study
(mean±SD age, 21±1 years; stature, 1.78±0.10 m; body mass, 69±11 kg;
maximum O2 uptake [Vo2max, 6.4±0.2 mL kg1 min1]. The participants were nonsmokers, free from cardiorespiratory disease, born and raised at <1500 m, and had
not travelled to elevations >1000 m in the 3 months prior to investigation.
Each subject was studied near sea level (SL) (130 m, average PB=749 mmHg)
and on the first and sixteenth days at Mt Chacaltaya, Bolivia (5260 m; average
PB=406 mmHg; AT1, AT16). Baseline studies at SL were conducted over a twoweek period in Eugene, OR, USA. Approximately one month after the SL studies,
subjects traveled to Bolivia in pairs on successive days. Upon arrival at El Alto
(4050m) after an overnight flight, subjects immediately descended to Coroico,
Bolivia (1525 m; PB=639 mmHg). Subjects rested for 48 hrs in Coroico to limit the
effects of jet lag and were then driven over three hrs to 5260 m. To provide an
acute change in inspired PO2 from 1525 m to 5260 m, subjects breathed
supplemental oxygen (2 L/min, nasal cannula or mask) during the drive. On arrival
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at 5260 m, the first subject immediately began the experimental protocol as
previously described92.
2.2.2 Metabolomic Profiling
Metabolomics extraction. RBCs (100 µl) were immediately extracted in icecold lysis/extraction buffer (methanol:acetonitrile:water 5:3:2) at 1:9 dilutions.
Samples were then agitated at 4°C for 30 min and then centrifuged at 10,000g for
15min at 4°C. Protein and lipid pellets were discarded, while supernatants were
stored at -80°C prior to metabolomics analyses93.
Metabolomics analysis. Ten µl of RBC extracts were injected into an UHPLC
system (Ultimate 3000, Thermo, San Jose, CA, USA) and run on a a Kinetex XBC18 column (150x2.1 mm i.d., 1.7 µm particle size – Phenomenex, Torrance, CA,
USA) using a 3min isocratic gradient at 250 µl/min (mobile phase: 5% acetonitrile,
95% 18 mΩ H2O, 0.1% formic acid). The UHPLC system was coupled online with
a QExactive system (Thermo, San Jose, CA, USA), scanning in Full MS mode (2
µscans) at 70,000 resolution in the 60-900 m/z range, 4kV spray voltage, 15 sheath
gas and 5 auxiliary gas, operated in negative and then positive ion mode (separate
runs). Calibration was performed before each analysis against positive or negative
ion mode calibration mixes (Piercenet – Thermo Fisher, Rockford, IL, USA) to
ensure sub ppm error of the intact mass. Metabolite assignments were performed
using the software Maven (Princeton, NJ, USA), upon conversion of raw files into
mzXML format through MassMatrix (Cleveland, OH, USA). The software allows for
peak picking, feature detection and metabolite assignment against the KEGG
pathway database. Assignments were further confirmed against chemical formula
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determination (as gleaned from isotopic patterns and accurate intact mass), and
retention times against a 619 standard compounds library including nucleosides
and nucleotide phosphates (SIGMA Aldrich, St. Louis, MO, USA; IROATech,
Bolton, MA, USA)93.
Relative quantitation was performed by exporting integrated peak areas
values into GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) for
statistical analysis (One way ANOVA with Tukey multiple column comparison test;
significance threshold for p-values < 0.01).
2.2.3 Mouse Subjects
Eight to ten-week-old C57BL/6 wild-type (WT) mice were purchased from
Harlan Laboratories (Indianapolis, IN). Ecto-5'-nucleotidase (CD73)-deficient mice
and A2B adenosine receptor (ADORA2B)–deficient mice with C57BL/6
background were generated and genotyped as described before 94. A novel line of
mice with erythrocyte specific deletion of Adora2b was generated by crossing mice
homozygous for a floxed Adora2b allele with mice expressing Cre recombinase
under the control of erythropoietin receptor (EpoR) gene regulatory elements 95. All
protocols involving animal studies were reviewed and approved by the Institutional
Animal Welfare Committee of the University of Texas Health Science Center at
Houston.
2.2.4 Blood collection and preparation
Human and mouse blood, respectively, were collected and stored as
described before 96, 97. Approximately 4 ml human blood was collected with heparin
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as an anti-coagulant for 2,3-bisphosphoglycerate (2,3-BPG) measurement (Roche)
as previous

96.

A portion of human blood was collected with EDTA as an anti-

coagulant for complete blood count (CBC). For plasma adenosine assay one ml of
the EDTA collected blood was aliquoted to tubes containing 10 μM dipyridamole
(an inhibitor of equilibrative nucleoside transporters) and 10 μM deoxycoformycin
(an inhibitor of adenosine deaminase). Approximately one ml Mouse blood was
collected similar to human blood as described above 98. Human blood was frozen
at -80℃ after collection and during shipment from the field until assay.
2.2.5 Measurement of soluble CD73 activity in mouse
sCD73 enzyme activity was measured by quantifying the rate of
ethenoadenosine (E-ADO) as described previously94. In brief, isolated plasma
were used for sCD73-specific activity measurement. First, 20μl plasma was
preincubated at room temperature with 200 nM deoxycoformycin (an inhibitor of
AMP-deaminase) in 0.1 M HEPES (pH 7.4), with 50 μM MgCl, with or without α,βmethylene ADP (APCP, Sigma-Aldrich, a specific inhibitor of CD73). Then,
samples were incubated at 37°C for 30 min in the presence of 100 μM E-AMP.
sCD73 activity was measured by determining E-ADO concentrations with reversed
phase HPLC as describe before. Absorbance was measured at 260 nm. sCD73
activity was expressed as the rate of E-ADO produced from E-AMP that is inhibited
by APCP.
2.2.6 Measurement of soluble CD73 activity in human
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Circulating CD73 enzyme activity in human was measured by quantifying the
rate of conversion of [3H]-AMP to [3H]-adenosine as described previously99, 100.
Briefly, sCD73 activity was measured after incubation of plasma with 300 uM
[3H]AMP (Quotient Bioresearch; GE Healthcare, Rushden, UK) for 60 min at 37°C.
Mixture then was applied onto Alugram SIL G/UV254 sheets (Macherey-Nagel,
Germany). Radiolabelled substrates and their products were separated by thin
layer chromatography (TLC) and quantified by scintillation β-counting.
2.2.7 Plasma adenosine measurement
Plasma adenosine concentration was measured by reversed phase HPLC as
previously described96,

98.

500 μl plasma was used to isolate adenosine by

sequentially adding 0.6 M cold perchloric acid, 3 M KHCO 3/3.6 N KOH, 1.8 M
ammonium dihydrogen phosphate (pH 5.1) and phosphoric acid (30%). Next, the
sample was centrifuged at 20,000 x g for 5 min and the supernatant was transferred
to a new tube and ready for reversed phase HPLC analysis. Adenosine content
was normalized to volume and expressed as a concentration.
2.2.8 Isolation of total erythrocytes and treatment of mouse erythrocytes in
vitro
Blood was collected with heparin as an anti-coagulant, and RBCs were
isolated by centrifugation at 240 x g for 10 min at room temperature. Packed red
blood cells (RBCs) were washed 3 times with culture media (F-10 nutrients mix,
Life Technology) and re-suspended to 4% hematocrit (HCT). One ml of RBCs was
added to each well of a 12-well plate96. Mouse RBCs were treated with AICAR
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(TOCRIS, USA) or AICAR (Sigma, USA) at 1mM for 4h under normoxic
conditions101. At the end of experiments, 2,3-BPG levels were measured, the
hemoglobin-O2 binding affinity were analyzed and calculated as P50 by Hemox
analyzer.
2.2.9

Hypoxyprobe

immunohistochemistry

in

multiple

organs

with

quantification
Tissue hypoxia levels were assessed by Hypoxyprobe immunohistochemistry
as described before102,

103.

Briefly, animals were administered Hypoxyprobe

(Hypoxyprobe, Inc.) via intraperitoneal injection (60 mg/kg body weight). One hour
after injection, tissues including hearts, lungs and kidneys were harvested, fixed
overnight in 4% buffered formalin, and embedded in paraffin. According to the
manufacturer’s instructions (Hypoxyprobe-1 Omni-Kit), sections of 4μm were cut
and mounted on glass slides, deparaffinized through serial baths in xylene and
rehydrated in a graded series of alcohol and distilled water. Endogenous
peroxidase activity was quenched by 10 min of incubation in a 3% hydrogen
peroxide/methanol buffer. Antigen retrieval was enhanced by autoclaving slides in
sodium citrate buffer (pH 6.0) at 95°C for 15 min. After blocking with a Biotin
Blocking System (Dako), the slides were then incubated with rabbit antiPAb2627AP in a humidified chamber at 4°C overnight. After the primary antibody
incubation, anti-rabbit IgG ABC staining system kit (VEACTASTAIN ABS-AP,
VECTOR LAB) was used according to the protocol. Slides were subsequently
stained with alkaline phosphatase substrate kit (VEACTASTAIN ABS-AP,
VECTOR LAB) and counterstained with hematoxylin. Quantification of the
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immunohistochemical staining was performed using the Image-Pro Plus software
(Media Cybernetics, Bethesda, MD). The density of the red staining was measured.
The average densities of 20 areas per samples were determined and the SEM is
indicated. (n=6)
2.2.10 Immunoprecipitation
Erythrocyte pellets were lysed in lysis buffer (1X TBS, 1% NP-40, 5 mM
EDTA), protease inhibitor cocktail (Sigma-Aldrich, MO), and phosphatase inhibitor
cocktail (Sigma-Aldrich, MO). The total protein concentration was measured with a
Protein Assay Kit (Bio-Rad). Cell lysates were precleared with 50 µl Protein A/G
Sepharose High Performance beads (GE Healthcare Life Sciences), and then
incubated overnight at 4oC with 50 µl antibody-bound beads prepared according to
manufacturer’s instructions and rocked gently. After immunoprecipitation, the
beads were washed 4 times with 1XTBS, and boiled with 2X Laemmli buffer for
Western blot analysis104.
2.2.11 Western blot analysis
Proteins in human and mice erythrocytes were analyzed by western blotting.
Frozen erythrocyte pellets were used for protein extraction following the protocol
as mentioned above. Proteins were run on 5-20% SDS-PAGE gels and transferred
to nitrocellulose membrane. After blocking (Odyssey Blocking Buffer, LI-COR),
membranes were incubated with antibody against BPG mutase (Santa Cruz), or
ADORA2B (Santa Cruz), or p-AMPK substrate (Cell Signaling), or AMPK
AMPK

and p-

(Cell Signaling) respectively as primary antibody. Afterwards, the
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membranes were probed with secondary antibodies antibody labeled with IRDye
fluorophores (LI-COR), subsequently scanned and detected by using the
ODYSSEY imaging system and software (LI-COR)97.
2.2.12 ELISA measurement of erythrocyte phosphorylation of AMPKα at
Thr172
Erythrocyte protein extraction from human blood were collected as described
above. Next, phosphorylation levels of erythrocyte AMPKα at Thr172 were
quantitatively measured by using commercially available ELISA kits. (A Solid
phase sandwich ELISA, Cell Signaling)
2.2.13 Mouse bone marrow cell culture to induce erythroid progenitor cells
and flow cytometry
Bone marrow cells (BMCs) were collected by flushing femur and tibias with
PBS from EpoR-Cre+ , Adora2bf/f/EpoR-Cre+ , and Adora2b-/-mice (8 to 10-weekold), and single-cell suspensions were obtained by passing through a cell strainer
and 21-gauge needle105. Next, hematopoietic progenitor cells (HPCs) were
enriched by negative selection using a mouse hematopoietic progenitor cell
enrichment kit (Easy Sep, StemCell Technologies)106. Briefly, isolated BMCs were
first incubated with a series of biotin-conjugated lineage antibodies (Abs) including
CD5, CD11b, CD19, CD45R, Ly-6G/C, and TER119 Abs, subsequently incubated
with magnetic beads. The differentiated cells expressing those lineage markers
bounded with magnetic beads were separated from undifferentiated HPCs by
magnetic bar. Then enriched HPCs lacking those lineage markers were further
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isolated by centrifugation. Purified HPCs were further seeded in wells (1x105
cells/ml), and cultured as previously described with modification for erythroid cells
differentiation106. In brief, cells were cultured in StemSpan™ Serum-Free
Expansion Medium (BSA, recombinant human insulin, human Transferrin, 2Mercaptoethanol, Iscove’s MDM) mixed with 15% FBS, 50 units/ml penicillin,
50ug/ml streptomycin, soluble erythropoietic factors and 2 units/ml EPO at 37°C in
a humidified atmosphere. After 2 days, the attached differentiated cells were
harvested. The percentage of early stage of erythroid progenitor cells were
determined by flow cytometry using FITC-conjugated CD71 (erythroid precursors
marker)106, 107. Harvested erythroid progenitor cells were used for quantification of
adora2b mRNA level by qRT-PCR as below.
2.2.14 qRT-PCR analysis of Adora2b mRNA in harvested erythroid
progentitor cells and tissues
RNA were extracted from harvested erythroid progenitor cells and mouse
lungs, then reverse transcription and real time-PCR were performed as previously
described97, 108. SYBR green was used for analysis of all the genes, and the relative
RNA levels were quantified as the ∆∆CT method 109. Primers: Mouse Adora2b:
forward;

5’-GCGAGAGGGATCATTGCTG-3’

5’CAGGAACGGAGTCAATCCAA-3’,Mouse

Gapdh:
and

TGACCTCAACTACATGGTCTACA-3’
CTTCCCATTCTCGGCCTTG-3’.
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and
forward;
reverse;

reverse;
5’5’-

2.2.15 Statistics
All data are expressed as the mean ± SEM. Data were analyzed for statistical
significance using GraphPad Prism 5 software (GraphPad Software). Two-tailed
Student’s t tests (paired or unpaired as appropriate) were applied in 2-group
analysis. Differences between the means of multiple groups were compared by
one-way analysis of variance, followed by a Turkey’s multiple comparisons test. P
value of less than 0.05 was considered significant. The relationship between two
variables X and Y were analyzed by Pearson product-moment correlation
coefficient method. P<0.05 (two-sided) was considered statistically significant. The
linear correlation (dependence) is described as R square.
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2.3 Results

2.3.1 Metabolomic screening reveals that altitude hypoxia activates the
Rapoport-Luebering Shunt in erythrocytes resulting in increased production
of 2,3-BPG and increased oxygen release from hemoglobin

To identify metabolic alterations in erythrocyte in response to hypoxia, we
conducted nonbiased high throughput metabolomic profiling of erythrocytes from
humans at sea level and at high altitude. Specifically, we recruited 21 young
healthy lowland volunteers who were examined at sea level and within two hours
of arrival at an altitude of approximately 5260 meters (ALT1) and on day 16 at high
altitude (ALT16) (Fig. 3). Overall, 233 metabolites were confidently identified and
relatively quantified out of over 9000 detected features (mass to charge ratios) in
the erythrocytes under sea level conditions and at high altitude (Table 2). Analysis
of these metabolic changes revealed that the erythrocyte-specific RapoportLuebering shunt, occurring at a branch point in the pathway of anaerobic glycolysis
for production of 2,3-BPG from 1,3-bisphoglycerate (1,3-BPG) (Fig. 4A), was
rapidly activated by high-altitude hypoxia. Specifically, levels of 2,3-BPG and its
upstream glycolytic intermediate, glyceraldehyde-3-phosphate (G3P), were
increased within 2 hr of arrival at high altitude (ALT1) and were further elevated
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on

day

16

(ALT16).

In

contrast,

the

levels

of

the

erythrocyte

monophosphoglycerates (3-PG and 2-PG) and phospoenolpyruvate (PEP), the
three immediate downstream products of 2,3-BPG, were significantly reduced on
day 1 and further reduced on day 16 at high altitude compared to sea level (Fig.
4B-E). To further validate our metabolomic screening, we accurately quantified
erythrocyte 2,3-BPG levels in human samples. Consistently, we found that
erythrocyte 2,3-BPG levels were significantly induced within two hours at high
altitude hypoxia and further elevated on day 16 at high altitude (Fig. 5). Thus, our
results indicate that in response to high altitude hypoxia the Rapoport-Luebering
Shunt is activated resulting in a significant portion of G3P being utilized to produce
2,3-BPG rather than directly metabolized to the glycolytic intermediate, 3-PG (Fig.
5).
Because 2,3-BPG is an allosteric modulator that decreases Hb-O2 binding
affinity and thereby promotes O2 release87, it is possible that hypoxia-induced 2,3BPG production in erythrocytes triggers O2 release. To test this possibility, we
quantified the O2 release capacity of erythrocytes by accurately measuring P50,
the partial pressure of O2 required to achieve 50% Hb-O2 saturation, from human
subjects at high altitude. We found that erythrocyte P50 values were significantly
elevated in human subjects after prolonged residence at that altitude (ALT16)
compared to two hours of arrival at 5260 m (ALT1). Finally, the ratio of
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(ALT16/ALT1) in erythrocyte 2,3-BPG levels upon extended stay at 5260 m was
significantly correlated with the ratio of (ALT16/ALT1) in erythrocyte P50, reflecting
reduced Hb-O2 binding affinity and enhanced erythrocyte O2 release capacity. No
differences were noted between male and female subjects (Fig. 6). These findings
provide evidence that high altitude hypoxia coordinately induces erythrocyte 2,3BPG production and P50 in humans adapting to high altitude (Fig. 4A).
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Figure.3. Table of human volunteer characteristics including age, height (HT), weight

(WT), body mass index (BMI), and schema for high altitude human studies. (n=21).
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Figure.4.

(A) Schematic drawing of erythrocyte-specific Rapoport-Luebering

shunt occurring at a branch point in the pathway of anaerobic glycolysis for 2,3bisphophoglycerate (2,3-BPG) production. (B-E) Metabolomic profiling reveals the
significant changes in the relative erythrocyte concentration of glyceraldehyde-3phosphate

(G3P)

(B),

bisphosphoglycerate

(BPG)

(C),

the

monophosphoglycerates, 2-phosphoglycerate (2-PG) and 3-phosphoglycerate (3PG) (D) and phophoenopyruvate (PEP) ) (E) at sea level (SL) and at high altitude
on day 1 and day 16. Data are expressed as mean ± SEM; *P<0.05 vs SL; **P<0.05
vs ALT1. AU (area under the peak)
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2.3.2 Extracellular adenosine concentrations and soluble CD73 activity
increase in humans at high altitude and increased adenosine is correlated
with elevated erythrocyte 2,3-BPG and O2 release capacity
Specific factors and signaling pathways involved in 2,3-BPG induction and
subsequent O2 release from erythrocytes under high altitude has not been
previously identified. Recent studies show that increased circulating adenosine is
involved in 2,3-BPG induction in erythrocytes of sickle cell disease (SCD)96.
However, whether adenosine signaling contributes to erythrocyte 2,3-BPG
induction and subsequent O2 release underlying high altitude hypoxia adaptation
remains unknown. To test this hypothesis, we used high performance liquid
chromatography (HPLC) to measure plasma adenosine levels in the 21 lowland
volunteers at sea level and following ascent to high altitude. We found that the
circulating adenosine levels were elevated within two hours of arrival at high
altitude compared to sea level and were further elevated on ALT16 following an
extended stay at 5260 m (Fig. 5). No significant differences in elevated plasma
adenosine levels were observed between males and females (Fig. 6). Ecto-5’nucleotidase (CD73) is an ectoenzyme anchored to the cell surface that plays a
key role in the synthesis of extracellular adenosine from AMP75. Under certain
circumstances, the ectoenzyme can be cleaved from the cell surface and exist in
the circulation as a soluble nucleotidase110. Therefore, we further measured
soluble CD73 (sCD73) activity in normal individuals at sea level and at high altitude.
Compared to sea level, sCD73 activity was significantly increased in the human
subjects within two hours following arrival at 5260 m (ALT1) and further increased
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following an extended stay at high altitude (AT16) (Fig. 5). There was no significant
difference in elevated sCD73 activity between males and females in response to
high altitude (Fig. 6).
Taken together, these results show that plasma adenosine concentration and
sCD73 activity increases rapidly in response to high-altitude hypoxia and that the
induction of plasma adenosine correlates with the induction of erythrocyte 2,3-BPG
level and O2 releasing capacity.
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activity. (A-F) Erythrocyte 2,3-BPG concentration, P50 level, plasma adenosine
concentration, soluble CD73 activity, p-AMPK levels, and 2,3-BPG mutase activity
were significantly elevated both in male and female at high altitude hypoxia, and
there were no significant differences between male and female. Data are
expressed as mean ± SEM; *P<0.05 vs SL; **P<0.05 vs ALT1.
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2.3.3. Soluble CD73 activity is induced under hypoxia and elevated CD73 is
essential for hypoxia-induced production of plasma adenosine and
increased erythrocyte 2,3-BPG level and O2 releasing capacity
Although extracellular adenosine is well-known to orchestrate a physiological
response to tissue injury and hypoxia, nothing is known about the functional role
of plasma adenosine in the normal erythrocyte under hypoxia. Our human studies
presented above raise an intriguing hypothesis that elevated plasma adenosine is
dependent on elevated CD73 and that elevated adenosine has a previously
unrecognized role in high altitude adaption by regulating 2,3-BPG production and
Hb-O2 binding affinity in erythrocytes. To test this hypothesis, we exposed WT and
CD73-deficient mice (Cd73-/-) to hypoxia (10% oxygen, similar to that at 5260 m)
for one week. Similar to the human high-altitude studies, we found that sCD73
activity, plasma adenosine levels, erythrocyte 2,3-BPG and P50 were significantly
increased in WT mice following 1 week of hypoxia compared to normoxia (Fig. 7AD). In contrast, hypoxia-mediated increased plasma adenosine, erythrocyte 2,3BPG and erythrocyte O2 releasing capacity were significantly impaired in Cd73-/mice (Fig. 7A-D). These results indicate that in mice sCD73 activity is induced by
hypoxia, as seen in human volunteers at high altitude, and that sCD73 is required
for hypoxia-induced plasma adenosine production and elevated erythrocyte 2,3BPG levels and O2 releasing capacity.
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Figure. 7 CD73 is essential for hypoxia-induced plasma adenosine,
erythrocyte 2,3-BPG concentration and P50 levels in mice. Plasma adenosine
concentration (A), soluble CD73 activity (B), Erythrocyte 2,3-BPG (C), and P50 (D)
in WT mice and Cd73-/- mice under normoxia or hypoxia (10% O2 1 week). Data
are expressed as mean ± SEM; *P<0.05 vs WT under normoxia; **P<0.05 vs WT
under hypoxia (n=10).
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2.3.4 CD73-mediated elevated extracellular adenosine protects against
tissue hypoxia in mice
To assess the functional importance of CD73-mediated increased plasma
adenosine in tissue, we measured the tissue hypoxia levels using a hypoxyprobe
in WT mice and Cd73-/- mice under normoxic conditions and following one week of
hypoxia as described above. No hypoxia signals were seen in tissue sections of
Cd73-/- or WT mice under normoxic conditions (Fig. 8A). However, under hypoxic
conditions, immunohistochemical (IHC) analysis with the hypoxyprobe revealed
that multiple organs including kidneys, lungs and hearts displayed mild hypoxic
signal in WT mice (Fig. 8A). In contrast, 7 days at 10% O2 led to severe hypoxia in
various organs including kidneys, lungs and hearts of Cd73-/- mice (Fig. 8A). Image
quantification analysis demonstrated that the intensity of hypoxyprobe in the
kidneys, lungs and hearts was significantly elevated in Cd73-/- mice compared to
WT mice (Fig. 8B-D). These results show that CD73-mediated elevation of plasma
adenosine plays a beneficial role to prevent tissue hypoxia in mice.

Hypoxia is known to induce lung injury including pulmonary vascular leakage
and inflammation111. Thus, we collected bronchoalveolar lavage fluid (BALF) of WT
and Cd73-/- mice for evaluation of pulmonary damage and inflammation.
Specifically, we quantified cell count, albumin concentration, and interleukin 6 (IL6) concentration in BALF of WT and Cd73-/- mice under normoxia and hypoxia.
Consistent with our tissue hypoxia staining and MPO activity measurements in the
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lung, cell count, albumin and IL-6 concentrations in BALF were slightly induced by
hypoxia in WT mice and their levels were significantly further increased in Cd73-/mice (Fig. 9A-D). Thus, these results show that CD73-mediated elevation of
plasma adenosine plays a beneficial role in preventing hypoxia-induced lung
damage and inflammation in mice.
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Figure. 8. (A-D) Deletion of Cd73-/- results in elevated tissue hypoxia under hypoxia
(10% O2 1 week). Immunohistochemical analysis of tissue hypoxia by hypoxyprobe.
(B-D) Semi-quantification of the hypoxyprobe staining in multiple tissues including
kidney, lung and heart of WT mice and Cd73-/- mice under normoxia or 10% O2 1
week hypoxia condition. Data are expressed as mean ± SEM; *P<0.05 vs WT under
normoxia; **P<0.05 vs WT under hypoxia (n=10; Scale bar=200M)
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Figure. 9. (A-D) Deletion of Cd73-/- results in elevated tissue inflammation infiltration in
multiple tissues, as well as pulmonary dysfunction under hypoxia (10% O2 1 week).
Analysis of tissue damage by Myeloperoxidase activity (B) in kidney, lung and heart.
Bronchoalveolar lavage fluid (BALF) total cell count (A), BALF albumin concentration
(C), BALF interleukin 6 concentration (D) in WT mice and Cd73-/- mice. Data are
expressed as mean ± SEM; *P<0.05 vs WT under normoxia;
hypoxia (n=10; Scale bar=200m).
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**

P<0.05 vs WT under

2.3.5 ADORA2B underlies hypoxia-induced 2,3-BPG production and oxygen
release capacity in in vitro cultured mouse erythrocytes
It is known that increased extracellular adenosine elicits physiological or
pathological functions by engaging its four adenosine receptors including ADORA1,
ADORA2A, ADORA2B, and ADORA3112. Each adenosine receptor has a distinct
cellular or tissue distribution and affinity for adenosine 113. To identify which
adenosine receptor is responsible for hypoxia-induced 2,3-BPG production and O2
release capacity in erythrocytes, we conducted genetic studies in four adenosine
receptor-deficient mice. We found that hypoxia significantly induced 2,3-BPG
production and O2 release capacity in cultured erythrocytes isolated from WT mice,
Adora1-deficient mice, Adora2a-deficient mice and Adora3-deficient mice.
However, hypoxia-mediated effects were absent in cultured erythrocytes isolated
from Adora2b-deficient mice (Fig. 11A-B), indicating that hypoxia-induced
erythrocyte 2,3-BPG production and O2 release capacity is dependent on
ADORA2B.
2.3.6 Genetic deletion of erythrocyte ADORA2B attenuates hypoxia-induced
2,3-BPG production and oxygen release capacity in vivo
To precisely determine the importance of erythrocyte ADORA2B-mediated
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elevated 2,3-BPG production and O2 release in hypoxia, we generated mice with
erythrocyte lineage-specific ablation of Adora2b genes by mating mice with floxed
Adora2b alleles (Adora2bf/f) with mice containing a transgene expressing Cre
recombinase only in the erythroid lineage (EpoR-Cre+). First, we validated the
specificity and efficiency of ablation of Adora2b in erythroid cells by EpoR-Cre
using bone marrow (BM) cells isolated from Epo-Cre+, Adora2bf/f/EpoR-Cre+ and
Adora2b-/- mice. The BM-derived hematopoietic progenitor cells (HPCs) were
enriched by negative selection, followed by induction to erythroid progenitor cells
in erythroid-differentiation medium containing erythropoietin (Fig. 10A). After two
days, we found that over 96% of harvested HPCs isolated and enriched from EpoCre+, Adora2bf/f/EpoR-Cre+ and Adora2b-/- mice were differentiated into CD71+
erythroid progenitor cells, which is consistent with a previous publication (Fig.
10B)106. Moreover, qRT-PCR analysis showed that erythrocyte lineage Adora2b
mRNA levels of Adora2bf/f/EpoR-Cre+ were reduced to levels similar to that of
Adora2b-/- mice, whereas pulmonary Adora2b mRNA levels in Adora2bf/f/EpoRCre+ were still similar to control mice (EpoR-Cre+) (Fig. 10C-D). These results
demonstrated that we had successfully generated mice with erythrocyte lineage
specific deletion of Adora2b.
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To test the functional role of erythrocyte ADORA2B signaling in response to
hypoxia, we exposed EpoR-Cre mice and Adora2bf/f/EpoR-Cre+ mice to normoxia
or hypoxia (10% O2) for one week. The levels of plasma adenosine, erythrocyte
2,3-BPG and P50 were similar in EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice
under normoxia (Fig. 11C-E). Following one week of hypoxia exposure, plasma
adenosine concentrations increased to similar levels in EpoR-Cre+ mice and
Adora2bf/f/EpoR-Cre+ mice (Fig. 11C). However, the hypoxia-induced erythrocyte
2,3-BPG production and P50 levels observed in the EpoR-Cre+ mice were
significantly attenuated in Adora2bf/f/EpoR-Cre+ mice (Fig. 11D-E). Thus, our
studies provide strong genetic evidence that mouse erythrocyte ADORA2B is
essential for elevated adenosine-mediated induction of erythrocyte 2,3-BPG and
O2 releasing capacity under hypoxia.
2.3.7 Erythrocyte ADORA2B is essential to protect against tissue hypoxia,
inflammation and lung damage
To further determine if erythrocyte ADORA2B signaling is tissue protective
under hypoxia, we assessed tissue hypoxia by hypoxyprobe in EpoR-Cre+ mice
and Adora2bf/f/EpoR-Cre+ mice following one week of hypoxia (10% O2). We found
that hypoxia treatment led to severe tissue hypoxia in various organs including
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kidneys, lungs and hearts in Adora2bf/f/EpoR-Cre+ mice, while only a mild hypoxia
signal was present in those tissues of EpoR-Cre+ mice (Fig. 12A). Image
quantification analysis demonstrated that the intensity of hypoxyprobe signals in
kidneys, lungs and hearts were significantly elevated in Adora2bf/f/EpoR-Cre+ mice
compared to EpoR-Cre+ (Fig. 12B-D) following hypoxia challenge. We also
observed greater elevation of MPO activity in kidney, lung and heart of
Adora2bf/f/EpoR-Cre+ mice compared to EpoR-Cre+ mice after hypoxia exposure
(Fig. 13A). Furthermore, greater lung injury reflected by increased cell counts,
albumin and IL-6 concentrations in BALF were detected in Adora2bf/f/EpoR-Cre+
mice after hypoxia challenge (Fig. 13B-D). These findings demonstrate that
erythrocyte ADORA2B is essential for tissue protection during hypoxia exposure.
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Figure. 12. Targeted deletion of erythrocyte ADORA2B results in elevated tissue
hypoxia (10% O2, 1 week). Immunohistochemical analysis of tissue hypoxia by
hypoxyprobe (A). Semi-quantification of the hypoxyprobe staining in multiple
tissues including kidney, lung and heart of EpoR-Cre+ and Adora2bf/f/EpoR-Cre+
mice under normoxia or 10% O2 1 week hypoxia condition (B-D). *P<0.05 vs EpoRCre+ mice under normoxia condition; **P<0.05 vs EpoR-Cre+ mice under hypoxia
condition. (n=10; Scale bar=200 M)
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Figure. 13. Myeloperoxidase activity (A) in kidney, lung and heart. Bronchoalveolar
lavage fluid (BALF) total cell count (B), BALF albumin concentration (C), BALF
interleukin 6 concentration (D) in EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice.
Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia;
**P<0.05

vs EpoR-Cre+ mice under hypoxia (n=10; Scale bar=200
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Figure 14. Erythrocyte ADORA2B is essential for hypoxia-induced p-AMPK, 2,3BPG mutase activity, 2,3-BPG concentration and P50 levels in vivo. Erythrocyte pAMPKα (quantified by ELISA) (A), 2,3-BPG mutase activity (B), 2,3-BPG
concentration (C) and P50 (D) of EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice
under normoxia or hypoxia (10% O2, 90% N2) for 1 day, 3 days, and 7 days. Data
are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia;
**P<0.05

vs EpoR-Cre+ mice under hypoxia for 1 day; #P<0.05 Adora2bf/f/EpoR-

Cre+ mice vs EpoR-Cre+ mice at the same time point (n=10).
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Figure 15. (E) Representative western blot and relative image quantification
analysis of p-AMPKα in erythrocytes of EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+
mice under normoxia or hypoxia (10% O2, 90% N2) for 1 week. (F) Representative
western blot and relative image quantification analysis of p-AMPK phosphorylated
2,3-BPG mutase levels in the erythrocyte lysates in EpoR-Cre+ mice and
Adora2bf/f/EpoR-Cre+ mice under normoxia or hypoxia (n=3). Data are expressed
as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia; **P<0.05 vs EpoRCre+ mice under hypoxia.
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Figure 16. AICAR treatment significantly stimulated hypoxia-induced erythrocyte
AMPK phosphorylation (A), 2,3-BPG mutase activity (B), 2,3-BPG production (C)
and P50 levels (D) compared to saline-treated group in Cd73-/- mice and
Adora2bf/f/EpoR-Cre+ mice under hypoxia (10% O2, 90% N2) for 3 days. Data are
expressed as mean ± SEM; *P<0.05 for AICAR-treated mice vs saline-treated mice
(n=8).
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2.3.8 AMPK functions downstream of erythrocyte ADORA2B in mice and
underlies hypoxia-induced 2,3-BPG production by phosphorylation and
activation of 2,3-BPG mutase
Erythrocyte 2,3-BPG is synthesized from the glycolytic intermediate 1,3-BPG
by 2,3-PBG mutase (Fig. 4A). Factors regulating 2,3-BPG production are poorly
understood. A previous report provided evidence that 2,3-BPG mutase is
associated with AMPK in erythrocyte lysates and may be a substrate of AMPK114.
Additional studies showed that ADORA2B signaling activates AMPK in other
cellular systems115. Like adenosine, AMPK plays a critical role in multiple cellular
functions especially under conditions of energy depletion and limited O2
availability116. However, whether AMPK functions downstream of ADORA2B as a
key enzyme responsible for hypoxia-induced 2,3-BPG production in erythrocytes
has not been previously studied. To test this possibility, we exposed EpoR-Cre
mice and Adora2bf/f/EpoR-Cre+ mice to hypoxia (10% oxygen, similar to that found
at 5260 m) for different time points. We found that erythrocyte AMPK
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG level and P50 are significantly
induced in EpoR-Cre mice after 1 day, 3 days and 7 days hypoxia treatment.
However, hypoxia induced elevation of AMPK phosphorylation, 2,3-BPG
mutase/synthase activity, 2,3-BPG and P50 are attenuated in Adora2bf/f/EpoRCre+ mice after 1 day, 3 days and 7 days hypoxia treatment (Fig. 14A-D). These
studies demonstrated that hypoxia is capable of inducing AMPK phosphorylation,
subsequently activate 2,3-BPG mutase, generate 2,3-BPG and trigger oxygen
release, and that erythrocyte ADORA2B is essential for this phenomenon in vivo.
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Next, we conducted experiments to assess the interaction between
erythrocyte AMPK and 2,3-BPG mutase and determine whether activated AMPK
phosphorylates 2,3-BPG mutase in erythrocytes. First, our immunoblots show that
basal AMPK phosphorylation levels, as judged by phosphorylation at threonine
172 (T172) of the subunit, in erythrocytes from Adora2bf/f/EpoR-Cre+ mice and
EpoR-Cre+ mice under normoxia were similar (Fig. 15A-B). Phosphorylation of
AMPK at T172 was significantly induced in erythrocytes of EpoR-Cre+ mice
following 1 week of hypoxia (10% O2). In contrast, phosphorylation of AMPK was
suppressed in Adora2bf/f/EpoR-Cre+ mice (Fig. 15A-B). Then, using an antibody
that recognizes phosphorylated AMPK (p-AMPK) substrates we showed that pAMPK specifically phosphorylates 2,3-BPG mutase and that under normoxic
conditions the levels of AMPK-phosphorylated 2,3-BPG mutase were similar in
Adora2bf/f/EpoR-Cre+ mice and EpoR-Cre+ mice(Fig. 15C-D). Subsequently, we
found that hypoxia significantly induced p-AMPK-phosphorylated 2,3-BPG mutase
in erythrocytes of EpoR-Cre+ mice and that this phosphorylation was significantly
attenuated in Adora2bf/f/EpoR-Cre+ mice (Fig. 15C-D). Thus, we conclude that
ADORA2B-induced AMPK phosphorylation, followed by p-AMPK-phosphorylated
2,3-BPG mutase are key steps in the signaling pathway underlying hypoxiainduced 2,3-BPG production and O2 release from erythrocytes to peripheral tissues
in mice.
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Figure 17. In vitro effects of AMPK activation in mouse erythrocytes.
(A-D) In vitro effects of AMPK activation. AMPK activator AICAR-induced p-AMPK
(A), 2,3-BPG mutase activity (B), 2,3-BPG concentration (C) and P50 levels (D) in
cultured erythrocytes isolated from WT mice in a time-dependent manner. While
Compound C significantly attenuated effects of AICAR treatment. Data are
expressed as mean ± SEM; *P<0.05 for AICAR-treated group 2-hour vs 1-hour,
and for AICAR-treated group 2-hour vs DMSO-treated group 2-hour, **P<0.05 for
AICAR-treated group 4-hour vs 2-hour, and for AICAR treated-group 4-hour vs
DMSO-treated group 4-hour. #P<0.05 for AICAR plus Compound C vs AICAR at
the same time point (n=8).
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Figure 18. In vivo effects of AMPK activation in mouse erythrocytes.
(A-D) In vivo effects of AMPK activation in mouse under normoxia. (E-H) AICAR
treatment (200mg/kg, IP) significantly stimulated erythrocyte p-AMPK (E), 2,3-BPG
mutase activity (F), 2,3-BPG production (G) and P50 levels (H) in WT mice
compared to saline-treated WT mice after 2 hours under normoxia. Data are
expressed as mean ± SEM; *P<0.05 Saline group vs AICAR-treated group (n=8).
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2.3.9 AMPK activators induce erythrocyte 2,3-BPG mutase activity, 2,3-BPG
production and O2 release in mouse in vitro and in vivo
Our discovery that erythrocyte AMPK is phosphorylated and subsequently
phosphorylates 2,3-BPG mutase in response to ADORA2B signaling suggests that
activation of AMPK may be sufficient to induce 2,3-BPG production by activating
2,3-BPG mutase. To test this possibility, we conducted in vitro studies to determine
if AMPK activation is sufficient to induce 2,3-BPG production and trigger oxygen
release in cultured WT mouse erythrocytes. Initially, we found that two independent
AMPK activators, AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide)
and AICAR, significantly induce phosphorylation of AMPK and activity of 2,3-BPG
mutase in a time dependent manner (Fig. 5a-b). Next, we found that both AMPK
activators significantly increased 2,3-BPG production and O2 releasing capacity in
cultured erythrocytes in a time dependent manner (Fig. 4c-d). Thus, in vitro studies
demonstrated that AMPK activation is sufficient to induce 2,3-BPG production and
enhanced O2 release

in mouse erythrocytes.

However, Compound

C

(dorsomorphin), a potent and selective inhibitor of AMPK, significantly attenuated
AICAR and AICAR mediated induction of AMPK phosphorylation, 2,3-BPG mutase
activity, 2,3-BPG and O2 releasing capacity in cultured mouse erythrocytes (Fig.
5a-d).
We extended our in vitro studies to further test if AICAR, a FDA approved
drug, could induce erythrocyte 2,3-BPG and O2 releasing capacity by stimulating
erythrocyte AMPK phosphorylation and 2,3-BPG mutase activity in WT mouse in
vivo. Our results (Fig. 5e-h) show that AICAR pretreatment significantly induced
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erythrocyte AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG level and
O2 releasing capacity in WT mouse in vivo.
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Figure 19.

In vivo effects of AICAR and Compound C treatment under

hypoxia.
(A-D) AICAR treatment significantly stimulated erythrocyte p-AMPK (A), 2,3-BPG
mutase activity (B), 2,3-BPG production (C) and P50 levels (D) in WT mice
compared to saline-treated WT mice under hypoxia (8% O2) in a time-dependent
manner, while Compound C treatment significantly attenuated erythrocyte p-AMPK
(A), 2,3-BPG mutase activity (B), 2,3-BPG production (C) and P50 levels (D) in WT
mice compared to saline-treated WT mice under hypoxia (8% O2). Data are
expressed as mean ± SEM; *P<0.05 for 6-hour vs basal level, **P<0.05 for 24-hour
vs 6-hour. #P<0.05 for AICAR-treated group vs saline group, and Compound Ctreated group vs saline group at the same time point (n=8).
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Figure 20. In vivo effects of AICAR or Compound C treatment on multiple
tissues in mice under hypoxia. IHC analysis of tissue hypoxia by hypoxyprobe
in kidney, lung and heart (E) Semi-quantification of the hypoxyprobe staining in
multiple tissues including kidney, lung and heart of WT mice under 8% hypoxia
condition for 24h with or without AICAR/Compound C treatment. Data are
expressed as mean ± SEM; *P<0.05 vs WT mice under normoxia condition;
**P<0.05 vs WT mice with saline treatment under hypoxia (n=8; Scale bar=200 M)
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Figure 21. AICAR treatment prevented tissue inflammation infiltration, while
Compound C treatment aggravated tissue MPO activity in WT mice under
hypoxia for 24 hours.
MPO activity in heart (A), kidney (B) and lung (C). AICAR or Compound Ctreated WT mice after 24 hours hypoxia treatment (n=8). Data are expressed as
mean ± SEM; *P<0.05 vs WT mice under normoxia; **P<0.05 vs WT mice with
saline treatment under hypoxia.
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2.3.10 In vivo effects of AMPK agonist in hypoxia adaptation in mouse
To test whether AICAR could prevent hypoxia-induced multiple tissue
damage in Cd73-/- and Adora2bf/f/EpoR-Cre+ mice by stimulating erythrocyte 2,3BPG production and O2 releasing capacity, we treated these mice with AICAR
under hypoxia (8% oxygen) for 3 days. Our results (Fig. 16A-D) show that AICAR
treatment restored erythrocyte 2,3-BPG levels and P50 in both Cd73-/- and
Adora2bf/f/EpoR-Cre+ mice under hypoxia.
To determine the in vivo effect of AMPK agonist in hypoxia adaptation in WT
mouse, we further extended our in vivo studies to treat WT mouse with AICAR
under hypoxia (8% oxygen) up to 24 hours. We found that AICAR treatment induce
greater elevation of erythrocyte 2,3-BPG and O2 releasing capacity by further
stimulating AMPK phosphorylation and 2,3-BPG mutase activity in WT mouse
compared to saline group under hypoxia (Fig. 18A-D). Further histological results
demonstrate that AICAR treatment significantly attenuated multiple tissue hypoxia
including lungs, kidneys and hearts in WT mouse compared to saline group under
hypoxia condition (Fig. 20A). Image quantification of hypoxyprobe staining
demonstrated that hypoxic levels were significantly reduced by AICAR treatment
in WT mouse (Fig. 20B-D). Next, to further determine the effect of AMPK inhibition
in erythrocyte hypoxia adaptation, we treat WT mice with Compound C under
hypoxia condition. In contrast, Compound C treatment reduce hypoxia-induced
AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and O2 releasing
capacity in WT mouse erythrocyte, thereby lead to enhanced multiple tissue
hypoxia including lungs, kidneys and hearts compared to saline group under
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hypoxia condition (Fig. 20A). Image quantification of hypoxyprobe staining
demonstrated that hypoxic levels were significantly induced by Compound C
treatment in WT mouse compared to saline group (Fig. 20B-D). Taken together,
these studies demonstrate that AICAR can override a genetic block to hypoxiainduced adenosine production (i.e., CD73 deficiency) or erythrocyte ADORA2B
signaling (erythrocyte-specific ADORA2B deficiency) to stimulate erythrocyte 2,3BPG production and O2 release by the pharmacologic activation of AMPK, and can
facilitate earlier hypoxia adaptation in WT mouse by rapidly inducing erythrocyte
AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and subsequent
O2 release to peripheral tissues.
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Figure 22. Erythrocyte p-AMPK and 2,3-BPG mutase activity are induced in
humans at high altitude
(A and B) Representative western blot and relative image quantification analysis
(n=3 per group) of p-AMPK levels quantified by ELISA C) and 2,3-BPG mutase
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activity (D) at high altitude ALT1 and ALT16 over SL. (E and F) Representative
western blot and relative image quantification analysis (n=3 per group) of p-AMPK
phosphorylated 2,3-BPG mutase at SL and high altitude on day 1 and day 16 in
erythrocyte lysates. Data are expressed as mean ± SEM; *P<0.05 for high altitude
on day 1 vs SL; **P<0.05 for high altitude on day 16 vs day 1.
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Figure 23. AMPK activation induces erythrocyte 2,3-BPG mutase activity, 2,3BPG production and oxygen release in cultured human erythrocytes
(A-D) AMPK activator AICAR-induced phosphorylation of AMPK (A), 2,3-BPG
mutase activity (B), 2,3-BPG concentration (C) and P50 levels (D) in cultured
normal human erythrocytes under normoxia in a time-dependent manner.
Compound C significantly attenuated the effect of AICAR treatment. Data are
expressed as mean ± SEM; *P<0.05 for AICAR-treated 2-hour group vs 1-hour
group, and for AICAR-treated 2-hour group vs DMSO-treated 2-hour group,
**P<0.05 for AICAR-treated 4-hour group vs 2-hour group, and for AICAR-treated
4-hour group vs DMSO-treated 4-hour group. #P<0.05 for AICAR plus Compound
C vs AICAR at the same time point (n=8). (E) Working model: CD73 is essential
for high altitude hypoxia-induced plasma adenosine production. Elevated plasma
adenosine prevents hypoxia-induced tissue inflammation and damage by
activating ADORA2B on erythrocytes to induce 2,3-BPG mutase activity, 2,3-BPG
production, and subsequently increased P50 and increased O 2 release to
peripheral hypoxic tissues. AMPK is a key enzyme that functions downstream of
ADORA2B to activate 2,3-BPG mutase, promote 2,3-BPG production and O2
release from erythrocytes. Thus, enhancing the CD73-ADORA2B-AMPK signaling
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pathway is a promising therapeutic strategy to treat or prevent hypoxia-induced
tissue damage.

2.3.11 AMPK activation-induced 2,3-BPG and O2 release via stimulating 2,3BPG mutase in human erythrocytes, and AMPK phosphorylation as well as
2,3-BPG mutase activity is significantly induced in humans at high altitude.
To determine the physiological function and significance of AMPK activation
in humans, we conducted a series of in vitro studies using human red blood cells.
First, AICAR and AICAR treatment directly induced AMPK phosphorylation, 2,3BPG mutase activity, 2,3-BPG and subsequent O2 release in cultured normal
human erythrocytes in a time dependent manner (Fig. 23A-D). To further determine
loss of function of AMPK activation in elevation of AMPK phosphorylation, 2,3-BPG
mutase activity, 2,3-BPG production and O2 release, we exposed AICAR and
AICAR treated human normal RBCs with or without compound C. We found that
compound C significantly suppressed AICAR and AICAR induced AMPK
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and O2 release in
cultured human normal RBCs (Fig. 23A-D).
Next, we further investigate whether increased AMPK phosphorylation and
2,3-BPG mutase activity occurs in human erythrocytes at high altitude. We
measured erythrocyte AMPK phosphorylation by western blot analysis in human
subjects at sea level and at high altitude on ALT1 and ALT16. We found that
erythrocyte p-AMPK levels were increased within two hours at high altitude (ALT1)
and were further elevated following an extended stay at high altitude (ALT16) (Fig.
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22A-B). In addition to western blotting we also used ELISAs to quantify erythrocyte
p-AMPK levels and found that p-AMPK levels were significantly increased on ALT1
and further elevated on ALT16 (Fig. 22C). No significant differences in elevated pAMPK levels were observed between male and female volunteers in response to
high altitude (Fig. 6D). Additionally, we demonstrated that erythrocyte 2,3-BPG
mutase activity were induced within two hours at high altitude (ALT1) and were
further elevated following an extended stay at high altitude (ALT16) (Fig. 22D)
Finally, we demonstrated that levels of AMPK-phosphorylated 2,3-BPG mutase in
erythrocytes were significantly increased at ALT1, and further enhanced on ALT16
(Fig. 22E-F). Altogether, we demonstrated that 1) high altitude induces erythrocyte
2,3-BPG mutase activity; 2) two independent AMPK agonists induce AMPK
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG production and subsequent O2
release in cultured human RBCs; 3) compound c inhibits AMPK activation and
subsequently suppresses AICAR and AICAR induce AMPK phosphorylation, 2,3BPG mutase activity, 2,3-BPG production and O2 release in cultured human RBCs.
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2.4 Discussion

It has been known for more than four decades that when humans ascend to
high altitudes the affinity of Hb for O2 is decreased to make more O2 available to
hypoxic peripheral tissues88, 117-119. It was also recognized early on that the reduced
O2 affinity was due in part to the increase in erythrocyte 2,3-BPG which functioned
as a negative allosteric regulator of Hb-O2 affinity87,

120, 121.

The molecular

mechanisms accounting for the altitude mediated regulation of erythrocyte 2,3BPG concentrations were not understood until we conducted non-biased
metabolomic screening of erythrocytes from a cohort of 21 human volunteers under
normoxia and high altitude hypoxia. We report here that Rapoport-Luebering Shunt
responsible for the production of erythrocyte 2,3-BPG is rapidly induced within two
hours of arrival at 5260 m and increases further upon prolonged stay at that altitude.
Additionally, we observed that plasma adenosine concentration and sCD73 activity
increased along with erythrocyte 2,3-BPG levels and O2 releasing capacity in
humans at high altitude. Using genetic tools, we demonstrated for the first time that
CD73-dependent elevation of plasma adenosine signaling via erythrocyte specific
ADORA2B is a key mechanism for hypoxia adaptation by inducing 2,3-BPG
production and triggering O2 release to counteract multiple tissue severe hypoxia.
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Mechanistically, we revealed that AMPK is a key enzyme that functions
downstream of ADORA2B signaling and contributes to hypoxia-induced 2,3-BPG
production and subsequent O2 release from erythrocytes in mice and humans.
Overall, both human and mouse studies reported here provide strong evidence
that CD73-dependent elevation of plasma adenosine, signaling via ADORA2B on
erythrocytes, plays a beneficial role in preventing altitude-mediated tissue hypoxia
by inducing 2,3-BPG production and triggering O2 release in a AMPK-dependent
manner (Fig. 23E). Thus, our findings reveal novel therapeutic targets to protect
against tissue hypoxia and provide a strong foundation for future clinical trials.

Although extracellular adenosine is known to be induced under hypoxia, no
prior study has reported that circulating adenosine levels are increased at high
altitude and a role of elevated adenosine in high altitude adaptation has never been
recognized prior to our study with young healthy human volunteers. Here we
discovered for the first time that plasma adenosine levels increased within two
hours of arrival at high altitude and increased further upon prolonged stay at 5260
m. Consistent with the altitude-dependent increase in plasma adenosine, we also
found that sCD73 activity was also significantly induced by high altitude. Moreover,
we confirmed early studies showing that erythrocyte 2,3-BPG and O2 releasing
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capacity are significantly elevated in humans at high altitude. The elevated plasma
adenosine concentrations is proportional to increased erythrocyte 2,3-BPG levels
and O2 releasing capacity. Although adenosine signaling regulates numerous
cellular and tissue functions by engaging its membrane receptors113,

122,

the

physiological function of adenosine and ADORA2B signaling in normal
erythrocytes in response to hypoxia was unknown.
Similar to humans at high altitude, we found that sCD73 activity, circulating
adenosine levels, erythrocyte 2,3-BPG levels and O2 releasing capacity were
significantly elevated in wild type mice maintained for 1 week at 10% O2 (equivalent
to the oxygen level at 5260 m). However, genetic deletion of CD73 significantly
reduced hypoxia-induced plasma adenosine, erythrocyte 2,3-BPG levels and O2
release capacity in the mice. The decreased O2 availability to peripheral tissues
resulted in multiple severely hypoxic tissues. Consistent with our findings, early
studies showed that genetic deletion of CD73 leads to vascular leakage and
increased immune cell infiltration in the lungs under hypoxic condition. 48,
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However, the functional role of CD73-dependent elevated circulating adenosine in
the induction of 2,3-BPG levels and O2 release capacity from normal erythrocytes
to protect hypoxic tissue damage was not recognized prior to our studies.
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Erythrocyte specific ADORA2B knockouts allowed us to demonstrate for the first
time that ADORA2B is essential for elevated plasma adenosine induced-2,3-BPG
production and O2 releasing capacity from erythrocytes. The ablation of erythrocyte
ADORA2B in mice results in severely hypoxic tissues, similar to CD73-deficient
mice. Thus, we have identified that elevated plasma adenosine signaling via
erythrocyte ADORA2B plays an important role in preventing multiple hypoxic
tissues by inducing erythrocyte 2,3-BPG levels and triggering O2 release to local
tissues. The discovery of this erythrocytes signaling pathway reveals the
importance of adenosine signaling in adaptation to high altitude hypoxia.
AMPK is a well-known metabolic stress-sensing kinase, which plays an
essential role in regulating cellular energy metabolism.123,

124

In erythrocytes,

AMPK plays critical roles in regulating oxidative stress and maintaining the integrity
and life span of the cell101, 125-127. A previous study used a proteomic approach to
identify 2,3-BPG-mutase as a potential AMPK target in erythrocytes 114. However,
a role for AMPK in 2,3-BPG induction under high altitude or hypoxic conditions in
normal erythrocytes has not been previously investigated. Our current work
revealed

that

AMPK,

functioning

downstream

of

ADOARA2B,

directly

phosphorylates and activates 2,3-BPG-mutase resulting in increased production of
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2,3-BPG, thereby promoting O2 release. Moreover, we demonstrated that two
independent AMPK activators (AICAR and AICAR) induce phosphorylation and
activation of 2,3-BPG mutase, 2,3-BPG production and O2 release in cultured WT
mouse erythrocytes. In contrast, Compound C, a potent and selective inhibitor of
AMPK, significantly attenuated effects of AICAR and AICAR in cultured WT mouse
erythrocytes. Because of the importance of AMPK in the induction of 2,3-BPG
production in erythrocytes, we conducted preclinical studies and found that
pretreatment with AICAR, a FDA-approved drug that has been used safely to treat
patients with type 2 diabetes since 1957128, prevented multiple severely hypoxic
tissues both in CD73-deficient mice and erythrocyte specific ADORA2B-deficient
mice by inducing erythrocyte 2,3-BPG levels and O2 availability to local tissue.
Moreover, we demonstrated that AICAR can induce earlier hypoxic adaptation by
rapidly inducing erythrocyte 2,3-BPG levels, triggering O2 release and thereby
prevent tissue hypoxia in WT mice. However, loss of function of AMPK by
Compound C treatment leads to suppression of erythrocyte AMPK phosphorylation,
2,3-BPG mutase activity, 2,3-BPG level and O2 release capacity, thereby abolish
effect of erythrocyte hypoxia adaptation resulting severe multiple tissue hypoxia.
The significance of our mouse finding was further supported by human translational
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studies showing that both AICAR and AICAR induce phosphorylation of AMPK and
activation of 2,3-BPG mutase, 2,3-BPG production and O2 release in cultured
normal human erythrocytes. In contrast, Compound C attenuate AMPK activationmediated AMPK phosphorylation, 2,3-BPG mutase activation, 2,3-BPG production
and O2 release in cultured normal human erythrocytes. Strikingly, AMPK
phosphorylation, 2,3-BPG mutase activity and levels of p-AMPK-phosphorylated
2,3-BPG mutase are significantly elevated in the erythrocytes of humans under
high altitude. Thus, preclinical studies in mice and translational studies with human
volunteers provide a strong foundation for future clinical trials in humans to test the
ability of AICAR to increase O2 availability in humans adapting to high altitude or
other hypoxic challenges. Moreover, future clinical trials to treat or prevent high
altitude sickness or other disease involving hypoxia-induced tissue damage should
be facilitated by the safety profile and FDA acceptance of AICAR (Fig. 23E).
In conclusion, we have identified a functional role of CD73-dependent
elevated extracellular adenosine signaling in O2 release from Hb in erythrocytes in
response to hypoxia. This discovery has revealed a previously unrecognized role
of adenosine signaling in erythrocyte physiology and provides a novel molecular
mechanism underlying adaptation to high-altitude hypoxia. Moreover, our finding
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that AMPK functioning downstream of ADORA2B in erythrocytes activates 2,3BPG mutase, subsequently resulting in increased 2,3-BPG production and
decreased Hb-O2 binding affinity, has important clinical implications. Overall, our
current studies have added significant insight to the molecular mechanisms
underlying human adaptation to hypoxia and thereby have opened up novel
therapeutic possibilities for prevention and treatment of hypoxia-related diseases.
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3 Chapter 3 Role of adenosine signaling in erythroid progenitors
3.1 Introduction
Approximately 1011 new RBCs are produced daily through proliferation and
differentiation of erythroid progenitors descent from hematopoietic stem cells
(HSC). This so-called erythropoiesis is a dynamic process finely regulated by
cytokines, hormones, growth factors, among others at transcriptional and
translational level129, 130. Stress-induced erythropoiesis is defined as a stimulated
basal erythropoiesis with expansion of the erythroid progenitor pool, resulting in
reticulocytesis and splenomegaly, in response to stress conditions including
anemia, hypoxia or infection.
Cell differentiation and proliferation is largely regulated by energy metabolism.
Although stress erythropoiesis has been long speculated to be linked with
increased metabolic requirements131, it is only until the recent several years with
innovative metabolomics profiling and state of art isotopically labelled metabolic
flux approaches132, the importance of fuel resources including glucose and
glutamine and their transport are revealed133. However, the molecular basis
promoting metabolic reprogramming to support erythropoiesis in response to
stress condition remains largely unknown.
Insufficient oxygen availability is one of the major stimulus for stress
erythropoiesis, inability to adapt to those stress conditions will result in multipletissue damage, stroke, cardiovasucular dysfunction and even death 89,

90, 134.

Previous studies have showed that adenosine signaling, a well-known key
regulator in response to stress condition, is involved in erythropoiesis135. However,
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whether adenosine signaling contributes to stress erythropoiesis is unknown.
Here, our mouse genetic studies showed that activation of adenosine
signaling via erythroid ADORA2B promotes the expansion of erythroid progenitors
both in spleen and bone marrow and in this way contributes to stress erythropoiesis
in two independent in vivo mouse models including hypoxia and PHZ-induced
anemia. Follow-up unbiased high-throughput metabolic profiling identified that
erythroid ADORA2B contributes to an overall hypoxia metabolic reprogramming
with substantial increased glycolysis, TCA cycle intermediates production in
erythroid progenitors in mice. Mechanistically, we showed that hypoxia-induced
factor 1 alpha (HIF-1) functions as downstream of erythroid ADORA2B regulating
hypoxia metabolic reprogramming by regulation of glucose and glutamine
metabolism and their transporters, subsequently modulates commitment of an
HSC to erythroid lineage. Taken together, our studies identify that adenosine
erythroid ADORA2B is a previously unrecognized purinergic signaling underlying
stress erythropoiesis by regulation of metabolic reprogramming in erythroid
progenitors, and likely discover novel therapeutic targets to counteract stressinduced injury by induction of erythropoiesis.
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3.2 Methods and material
3.2.1 Mouse Subjects
Eight to ten-week-old C57BL/6 wild-type (WT) mice were purchased from
Harlan Laboratories (Indianapolis, IN). Ecto-5'-nucleotidase (CD73)-deficient mice
and A2B adenosine receptor (ADORA2B)–deficient mice with C57BL/6
background were generated and genotyped as described before 94. A novel line of
mice with erythrocyte specific deletion of Hif-1 was generated by crossing mice
homozygous for a floxed Hif-1 allele with mice expressing Cre recombinase
under the control of erythropoietin receptor (EpoR) gene regulatory elements 95. All
protocols involving animal studies were reviewed and approved by the Institutional
Animal Welfare Committee of the University of Texas Health Science Center at
Houston.
3.2.2 Plasma Epo measurement
Blood was collected with heparin as an anti-coagulant, and plasma were
collected by centrifugation at 2000 x g for 20 min at room temperature. Then the
plasma Epo concentration was measured by using commercial ELISA kits. (R&D
System, Inc.)
3.2.3 Flow cytometry
For flow cytometry analyses, single cell suspensions were first prepared from
blood, spleen, or bone marrow. ~5x105 cells were washed with PBS/2%FBS (wash
buffer), then incubated with 1-2µg/ml indicated antibodies 30mins at 4°C. Mouse
antibodies used including CD11b-APCCy7, CD71-PECy7, Gr1-APCCy7, Ter119Pacific blue (all from Biolegend). Cells were additionally stained with matching
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isotype controls. For viability assessments, cells were stained with annexin V-APC
in conjunction with 7-AAD. Cells were then washed with wash calcium binding
buffer. Data was acquired with a Beckman-Coulter Gallios Flow Cytometer and
analyzed with Kaluza1.5 software as previously136.
3.2.4 RT-PCR
RNA extraction, reverse transcription and real time-PCR were performed as
previously described97, 108. SYBR green was used for analysis of all the genes, and
the relative RNA levels were quantified as the ∆∆CT method 109. Primers: Mouse
Adora1:

forward;

5’-TGTGCCCGGAAATGTACTGG-3’
Mouse

TCTGTGGCCCAATGTTGATAAG-3’,

Adora2a:

and

GCCATCCCATTCGCCATCA-3’

reverse;
forward;

reverse;

Mouse

GCAATAGCCAAGAGGCTGAAGA-3’,

and

Adora2b:

forward;

5’5’5’5’-

GCGAGAGGGATCATTGCTG-3’ and reverse; 5’-CAGGAACGGAGTCAATCCAA3’, Mouse Adora3: forward; 5’-ATACCAGATGTCGCAATGTGC-3’ and reverse; 5’Gapdh:

GCAGGCGTAGACAATAGGGTT-3’,Mouse

and

TGACCTCAACTACATGGTCTACA-3’
CTTCCCATTCTCGGCCTTG-3’;

Mouse
and

GAAATGGCCCAGTGAGAAAA-3’
CTTCCAVGTTGCTGACTTGA-3’.
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HIF-1:

forward;
reverse;
forward;
reverse;

5’5’5’5’-

3.2.5 Mouse bone marrow stem cell culture ex-vivo
Bone marrow cells (BMCs) from WT mice and Adora2b -/- were collected as
described in Chapter 2. Cultured cells were harvested at 0, 24h and 48h time points
and then detected by flow cytometry106, 107.

3.3 Results
3.3.1 Elevated CD73-mediated plasma adenosine is essential for hypoxiainduced erythroid commitment and erythropoiesis in mice independent of
plasma erythropoietin
To determine whether adenosine contributes to the hypoxia-induced stress
erythropoiesis, we exposed wild type mice (WT) and CD73-deficient mice (Cd73-/-)
to hypoxia (10% O2) up to 72h. We found that the soluble CD73 (sCD73) activity
and levels of plasma adenosine were induced after hypoxia exposure in WT mice
in a time-dependent manner (Fig. 24A-B). Moreover, eythropoiesis-related
parameters including percentage of reticulocyte and spleen size were significantly
induced in response to hypoxia compared to normoxia in WT mice (Fig. 24D-E).
However, hypoxia-mediated elevation of sCD73, increased plasma adenosine
level and induction of erythropoiesis were significantly suppressed in Cd73-/- mice
compared to WT mice. In contrast, plasma erythropoietin (Epo) levels were no
significant difference between WT and Cd73-/- mice under normoxia or hypoxia
condition (Fig. 24A-E). Erythropoiesis was detected by flow cytometry in WT mice
including increased percentage of splenic CD71+ and Ter119+ erythroid progenitors
in response to hypoxia compared to normoxia, with a similar trend in bone marrow
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(Fig. 25A). To further evaluate erythroid lineage differentiation, I assessed the
Ter119+ cells on the basis of CD71 staining from stage I to stage IV which
represents undifferentiated cells to differentiated cells (Fig. 25B). Hypoxia-induced
expansion of erythroid progenitors was induced most in the stage II of erythroid
progenitors in WT mice, but was suppressed in Cd73-/- mice. In contrast, attenuated
myeloid lineage (CD71-CD11b+, CD71-Gr1+) was detected in bone marrow in WT
mice as compared to Cd73-/- mice after hypoxia exposure (Fig. 25C). Thus, here I
provide genetic evidence that CD73-mediated increased plasma adenosine is
required

for

hypoxia-induced

erythroid

independent of plasma Epo level.
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commitment

and

erythropoeisis
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Figure24. Elevated CD73-mediated adenosine induction is essential for
hypoxia-induced

erythropoiesis

in

mice

independent

of

plasma

erythropoietin
(A-C) Soluble CD73 (sCD73) activity and levels of plasma adenosine were induced
after hypoxia exposure in WT mice, but not in Cd73-/- mice in a time-dependent
manner. Data are expressed as mean ± SEM; *P<0.05 vs WT under normoxia;
**P<0.05

vs WT under 48h hypoxia (n=10) (C) No difference of elevated

erythropoietin (Epo) level was detected between WT and Cd73-/- mice under
normoxia or hypoxia condition. Splenomegaly (D) and percentage of reticulocyte
(E) and were significantly induced in response to hypoxia compared to normoxia
in WT mice, but not in Cd73-/- mice in a time-dependent manner. Data are
expressed as mean ± SEM; *P<0.05 vs WT under normoxia; **P<0.05 Cd73-/- vs
WT under hypoxia (n=10).
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Figure. 25. Elevated CD73-mediated adenosine induction is essential for
hypoxia-induced erythroid expansion in mice
(A) Robust erythropoiesis was detected by flow cytometry in WT mice including
increased percentage of splenic CD71+ or Ter119+ or CD71+/Ter119+ erythroid
progenitors in response to hypoxia compared to normoxia. (B) Erythroid lineage
differentiation, reflected by the assessment of Ter119+ cells on the basis of CD71
staining from stage I to stage IV. Hypoxia-induced expansion of erythroid
progenitors was induced the most in the stage II of erythroid progenitors in WT
mice, but was suppressed in Cd73-/- mice. (n=10). Data are expressed as mean ±
SEM.
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3.3.2 Adenosine signaling contributes to stress erythropoiesis via erythroid
ADORA2B
There are four GPCR adenosine receptors including ADORA1, ADORA2A,
ADORA2B, and ADORA3. To determine which adenosine receptor is primarily
involved in elevated plasma adenosine-mediated stress erythropoiesis in response
to hypoxia, we specifically isolated the stage II of CD71+Ter119+ splenic erythroids,
and subsequently assessed the adenosine receptor expression level by qRT-PCR.
We found that Adora2b was highly expressed in the CD71+Ter119+ erythroids
compared to the other three adenosine receptors

and that Adora2b gene

expression was induced the most in these cells under hypoxia compared to
normoxia (Fig. 26A) , implicating that ADORA2B is likely the major adenosine
receptor underlying elevated plasma adenosine-induced erythropoiesis under
hypoxia. To test this hypothesis, we exposed EpoR-Cre+ mice (control) and
Adora2bf/fEpoR-Cre+ mice (erythroid specific ablation of Adora2b genes) to
normoxia or hypoxia (10% O2) up to 72h. 10% O2 hypoxia induced similar levels
of plasma adenosine in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice. However,
hypoxia-induced erythropoiesis featured with increased percentage of reticulocyte
and splenomegaly were significantly attenuated in Adora2bf/fEpoR-Cre+ mice
compared to EpoR-Cre+ mice (Fig. 26B-C). In addition, genetic deletion of erythroid
ADORA2B significantly attenuated hypoxia-induced population of stage IICD71+Ter119+ erythroids in Adora2bf/fEpoR-Cre+ mice compared to EpoR-Cre+
mice. Similar trend were observed in the bone marrow (Fig. 27A). In contrast, Epo
levels were elevated to a similar extent in EpoR-Cre+ mice and Adora2bf/fEpoRCre+ mice under hypoxia (Fig. 26D). Furthermore, attenuated myeloid lineage
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(CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+, Ter119-Gr1+) was detected in bone
marrow of EpoR-Cre+ mice as compared to Adora2bf/fEpoR-Cre+ mice (Fig. 27BE). Thus, I provides genetic evidence that adenosine signaling via erythroid
ADORA2B contributes to hypoxia-induced erythropoiesis by regulation of erythroid
commitment of HSCs independent of plasma Epo level.
3.3.3 ADORA2B is critical for commitment of hematopoietic precursors to
erythroids by regulation of metabolic reprogramming in response to stress
condition
Metabolic pathways and their regulation has been reported to play an
essential role in proliferating cells. Therefore, stress erythropoiesis with
substantially stimulated proliferation and differentiation of erythroid progenitors has
been speculated to be linked with increased metabolic requirements, and nutrient
including glucose and glutamine were considered as essential supply for the
erythroid commitment from hematopoietic stem cells.
Although we showed that erythroid ADORA2B is the specific receptor underlying
adenosine-mediated expansion of erythroid progenitors and subsequent
contribution of erythropoiesis in response to hypoxia, the intracellular mechanism
is still unclear. Therefore, to explore the mechanism underlying adenosine
ADORA2B-induced expansion of erythroid cells under stress condition, I
conducted

unbiased

high

throughput

metabolomic

screening

in

CD71high/Ter119high progenitors isolated from spleen of EpoR-Cre+ mice and
Adora2bf/fEpoR-Cre+ mice under normoxia and 72 hour hypoxia. Overall, 233
metabolites were identified and quantified out of over 9000 detected features
(mass to charge ratios) in these cells. Analysis of these metabolic changes
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revealed that glucose metabolism including glycolysis, pentose phosphate
pathway (PPP), glutamine metabolism and glutathione pathway are the most
induced in control mice under hypoxia. In contrast, hypoxia induced glycolysis,
TCA cycle intermedaites and glutaminolysis were significantly suppressed in
Adora2bf/fEpoR-Cre+ mice. Thus, our metabolomic profiling demonstrated for the
first time that ADORA2B has a previously unrecognized role in "hypoxic metabolic
reprogramming" to enhance glucose and glutamine metabolism thus promote
stress erythropoiesis.
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Figure. 26. Adenosine signaling via ADORA2B on erythroid progenitors
contributes to stress erythropoiesis
(A) Four adenosine receptors including ADORA1, ADORA2A, ADORA2B, and
ADORA3 Adora2b were assessed in the isolated CD71+Ter119+ splenic erythroids
under normoxia and 72h hypoxia. (B-C) Hypoxia-induced erythropoiesis featured
with increased percentage of reticulocyte and splenomegaly in EpoR-Cre+ mice,
was suppressed in Adora2bf/fEpoR-Cre+ mice. (D) Similar plasma Epo levels in
EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice under hypoxia. Data are
expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ under normoxia; **P<0.05
EpoR-Cre+ vs Adora2bf/fEpoR-Cre+ under hypoxia (n=10).
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Figure. 27. Adenosine signaling via ADORA2B on erythroid progenitors
regulates erythroid commitment under hypoxia
(A) Genetic deletion of erythroid ADORA2B significantly attenuated hypoxiainduced population of stage II-CD71+Ter119+ erythroids in Adora2bf/fEpoR-Cre+
mice compared

to EpoR-Cre+ mice. (B-E) Enhanced erythroid lineage

(CD71+CD11b-, CD71+Gr1-, Ter119+CD11b-, Ter119+Gr1-), and attenuated
myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+, Ter119-Gr1+) were
detected in EpoR-Cre+ mice as compared to Adora2bf/fEpoR-Cre+ mice after 72h
hypoxia exposure. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+
under normoxia;

**P<0.05

EpoR-Cre+ vs Adora2bf/fEpoR-Cre+

(n=10).
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under hypoxia

3.3.4 Erythroid HIF-1 underlies ADORA2B contributes to hypoxia-induced
stress erythropoiesis by regulation of erythroid commitment
How

adenosine

erythroid

ADOA2B

signaling

regulates

metabolic

reprogramming, and subsequent control of the commitment of erythroid lineage
from HSCs is still unknown. Previous study showed that HIF-1 activation
increases Adora2b gene expression under hypoxia. More recently, multiple studies
showed that ADORA2B feedback induces Hif-1

gene expression in other

cellular systems. Further, RNA deep sequencing revealed that glucocorticoidinduced proliferation of erythroid progenitor cells was largely associated with HIF1 activation. Thus, I hypothesize that HIF-1 and ADOAR2B reciprocally
upregulate each other in erythroid progenitor to promote stress erythropoiesis. To
test this hypothesis, we conducted RT-PCR to show that Hif-1 mRNA is
significantly induced in these progenitor cells isolated from EpoR-Cre+ mice under
hypoxia, but not in Adora2bf//fEpoR-Cre+ mice, indicating that ADORA2B induces
Hif-1 gene expression under hypoxia in erythroid progenitor cells (Fig. 28A). Next,
to determine the functional role of HIF-1 in hypoxia-induced erythropoiesis, we
generated Hif-1f/fEpoR-Cre+ erythroid-specific HIF-1 knockouts by mating Hif1

f/f

mice with EpoR-Cre+ mice. Intriguingly, we found robust hypoxia-induced

stress erythropoiesis reflected by increased spleen size and percentage of
reticulocyte in EpoR-Cre+ mice control mice, was suppressed in Hif-1f/fEpoR-Cre+
mice (Fig. 28B-C). Moreover, we found that genetic deletion of erythroid HIF-1
significantly reduced population II of CD71+Ter119+ proerythroblast progenitors in
spleen compared to EpoR-Cre+ control mice after 72 hour hypoxia exposure
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(Fig. 28D). Taken together, this provides genetic and pharmacological evidence
that

ADORA2B-HIF-1

pathway

contributes

erythropoiesis.

104

to

hypoxia-induced

stress
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Figure. 28. Erythroid HIF-1 contributes to hypoxia induced stress
erythropoiesis (A) RT-PCR results showed that Hif-1 mRNA is significantly
induced in isolated CD71+Ter119+ splenic erythroids in EpoR-Cre+ mice under
hypoxia, but not in Adora2bf/fEpoR-Cre+ mice. (B-C) Hypoxia-induced stress
erythropoiesis reflected by increased spleen size and percentage of reticulocyte in
EpoR-Cre+ mice control mice, but was suppressed in Hif-1f/fEpoR-Cre+ mice. (D)
Genetic deletion of erythroid HIF-1 significantly reduced population II of
CD71+Ter119+ proerythroblast progenitors in spleen compared to EpoR-Cre+
control mice after 72 hour hypoxia exposure. Data are expressed as mean ±
SEM; *P<0.05 vs EpoR-Cre+ under normoxia;
1f/fEpoR-Cre+ mice under hypoxia (n=10).
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**P<0.05

EpoR-Cre+ vs Hif-

3.3.5 Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in Adora2bf/fEpoR-Cre+ mice in acute anemia model
Acute anemia is a life-threatening phenomenon when HCT levels drop
dramatically in a short period of time, especially in stress conditions. To assess the
clinical relevance of impaired stress erythropoiesis in Adora2b-/- mice, we utilized a
phenylhydrazine (PHZ)-induced hemolytic model, which is a well-accepted stress
erythropoiesis model. 8-12 week old adult mice were consecutive injected with
PHZ at day 0, 1 and 3 as previously, and erythropoietic parameters were detected
at day 5. PHZ-treated EpoR-Cre+ mice showed active erythropoiesis at the day 5
including recovered HCT levels, increased percentages of CD71+ and Ter119+
erythroid progenitors in bone marrow. However, impaired erythropoiesis was
detected in PHZ-treated Adora2bf/fEpoR-Cre+ mice. In contrast, suppressed
myeloid lineage reflected by CD11b+ staning was detected in EpoR-Cre+ mice,
while enhanced levels in Adora2bf/fEpoR-Cre+ mice after PHZ treatment (Fig. 29AG). To further evaluate erythroid lineage differentiation, we assessed the Ter119+
cells on the basis of CD71 staining from stage I to stage IV. Intriguingly, PHZinduced expansion of erythroid progenitors was induced the most in the stage II of
proerythroblasts in EpoR-Cre+ mice, but was suppressed in Adora2bf/fEpoR-Cre+
mice (Fig. 30A).
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3.3.6 Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice in acute anemia model
To further evaluate the impact of HIF-1 in acute anemia-induced stress
erythropoiesis model, EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice were treated
with consecutive injection of PHZ at day 0, 1 and 3 as previously, and erythropoietic
parameters were detected at day 5. PHZ-treated EpoR-Cre+ mice showed an
active erythropoiesis at the day 5 including recovered their HCT levels, increased
percentages of CD71+ and Ter119+ erythroid progenitors in bone marrow. However,
impaired erythropoiesis was detected in PHZ-treated Hif-1f/fEpoR-Cre+ mice. In
contrast, suppressed percentage of myeloid lineage reflected by CD11b+ was
detected in EpoR-Cre+ mice, while enhanced levels in Hif-1f/fEpoR-Cre+mice after
PHZ treatment (Fig. 31A-G). To further evaluate erythroid lineage differentiation,
we assessed the Ter119+ cells on the basis of CD71 staining from stage I to stage
IV. Intriguingly, PHZ-induced expansion of erythroid progenitors was induced the
most in the stage II of proerythroblasts in EpoR-Cre+ mice, but was suppressed in
Hif-1f/fEpoR-Cre+ mice (Fig. 32A).
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Figure. 29. Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cells in Adora2bf/fEpoR-Cre+ mice in acute anemia model
(A-G) Representative flow cytometry results showed that lower HCT level,
suppressed percentages of CD71+ and Ter119+ erythroid progenitors, but higher
CD11b myeloid progenitors in Adora2bf/fEpoR-Cre+ mice as compared to EpoRCre+ mice after phenylhydrazine (PHZ) challenge. Data are expressed as mean ±
SEM; *P<0.05 vs EpoR-Cre+ after PHZ challenge (n=8).
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Figure. 30. Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in Adora2bf/fEpoR-Cre+ mice after PHZ challenge
Erythroid lineage differentiation in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice
were assessed by flow cytometry by quantifying percentage of Ter119 + cells on the
basis of CD71 staining from stage I to stage IV after PHZ challenge. Erythroid
commitment in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice were assessed by
flow cytometry by quantifying percentage of erythroid lineage (CD71 +CD11b-,
Ter119+CD11b-,), and myeloid lineage (CD71-CD11b+, Ter119-CD11b+) after PHZ
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ
challenge (n=8).
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Figure. 31. Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice in acute anemia model
(A-G) Representative flow cytometry results showed that lower HCT level,
suppressed percentages of CD71+ and Ter119+ erythroid progenitors, but higher
CD11b myeloid progenitors in Hif-1f/fEpoR-Cre+ mice as compared to EpoR-Cre+
mice after phenylhydrazine (PHZ) challenge. Data are expressed as mean ± SEM;
*P<0.05 vs EpoR-Cre+ after PHZ challenge (n=8).
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Figure. 32. Impaired commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice after PHZ challenge
Erythroid lineage differentiation in EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice
were assessed by flow cytometry by quantifying percentage of Ter119 + cells on the
basis of CD71 staining from stage I to stage IV after PHZ challenge. Erythroid
commitment in EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice were assessed by
flow cytometry by quantifying percentage of erythroid lineage (CD71 +CD11b-,
Ter119+CD11b-,), and myeloid lineage (CD71-CD11b+, Ter119-CD11b+) after PHZ
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ
challenge (n=8).
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Figure. 33. CD73-mediated elevated circulating adenosine is responsible for
increased stress erythropoiesis in SCD Tg mice
(A) Plasma adenosine were induced SCD Tg mice as compared to in WT mice,
but genetic deletion of CD73 in SCD Tg mice background significantly attenuated
plasma adenosine. (B-D) Splenomegaly and percentage of reticulocyte were
significantly increased in SCD Tg mice as compared in WT mice, but genetic
deletion of CD73 in SCD Tg mice background significantly attenuated increased
spleen size and reticulocyte percentage. Data are expressed as mean ± SEM;
*P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD (n=10).
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Figure. 34. Enhanced erythroid lineage versus myeloid lineage in SCD Tg
mice
(A-C) Increased erythroid lineage reflected by percentage of splenic CD71 + and
Ter119+ cells, and decreased myeloid lineage reflected by percentage splenic
CD11b+ cells were detected by flow cytometry in SCD Tg mice but not in
SCD/CD73 mice as compared to WT mice. Data are expressed as mean ± SEM;
*P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD (n=10).

120

121

Figure. 35. (A-B) Erythroid lineage differentiation, reflected by assess the Ter119+
cells on the basis of CD71 staining from stage I to stage IV. Expansion of erythroid
progenitors was induced the most in the stage II of erythroid progenitors in SCD
Tg mice, but was suppressed in SCD/CD73 mice as compared to WT mice. Data
are expressed as mean ± SEM; *P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD
(n=10).
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Figure. 36. Increased commitment of erythroid versus myeloid lineage from
hematopoietic stem cell in SCD Tg mice in a CD73 dependent manner
(A-D) Erythroid commitment were assessed by flow cytometry by quantifying
percentage of erythroid lineage (CD71+CD11b-, CD71+Gr1-, Ter119+CD11b-,
Ter119+Gr1-), and myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+,
Ter119-Gr1+). Data are expressed as mean ± SEM; *P<0.05 vs WT mice; **P<0.05
SCD/CD73 vs SCD (n=10).
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3.3.7 CD73-mediated elevation of plasma adenosine is responsible for stress
erythropoiesis in humanized sickle cell disease mouse model
Sickle cell disease (SCD) is an inherited blood disorder that results from a
mutation in hemoglobin, the protein that carries O2 in erythrocytes throughout our
bodies. The mutant hemoglobin causes the erythrocytes to acquire an unusual
sickle shape that hinders movement through blood vessels. The clumps of sickled
cells block blood flow resulting in pain, serious infections, and organ damage. It is
widely accepted that SCD is a type of chronic hypoxia disease model due to the
abnormal erythrocyte. Previous studies reported that stress erythropoiesis was
occurred in SCD patients, and our current results showed that activated
erythropoiesis was observed in SCD transgenic (Tg) mice. However, the molecular
mechanism involved in activated erythropoiesis in SCD is unclear. Our previous
studies showed that plasma adenosine is highly induced in both SCD patients and
SCD Tg mice, and attenuation of circulating adenosine levels by PEG-ADA
enzyme therapy significantly decreases erythropoietic parameters including spleen
size and percentage of reticulocyte in SCD Tg mice, indicating that elevated
plasma adenosine likely contributes to the stress erythropoiesis in SCD Tg mice96.
To test this hypothesis, we further deletion the CD73, a key enzyme generates
adenosine extracellularly, in the background of SCD Tg mice. First, our HPLC
results showed that plasma adenosine level was significantly attenuated in
SCD/CD73 double knockout mice (Fig. 33A). Then, we showed that decreased
plasma adenosine leads to suppressed percentage of reticulocyte and spleen size
in SCD/CD73 double knockout mice compared to SCD Tg mice (Fig. 33B-D).
Robust erythropoiesis was detected by flow cytometry in bone marrow reflected by
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enhanced erythroid lineage including increased CD71 + population, Ter119+
population, and CD71+/Ter119+ population. However, activation of erythropoiesis
was significantly attenuated in SCD/CD73 double knockout mice compared to
SCD Tg mice. In addition, genetic deletion of CD73 in SCD Tg mice significantly
attenuated elevation of stage II-CD71+Ter119+ erythroids compared to SCD Tg
mice. Similar features were observed in the spleen (Fig. 34A-B and Fig. 35A-C).
Intriguingly, enhanced myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119CD11b+, Ter119-Gr1+) was detected in SCD/CD73 double knockout mice as
compared to SCD mice (Fig. 36A-D). Thus, this provides genetic evidence that
adenosine signaling contributes to stress erythropoiesis by regulation of erythroid
commitment of HSCs in SCD Tg mice.
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Figure 37. Working model of role of adenosine signaling in stress
erythropoiesis
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3.4 Discussion
Erythropoiesis, the formation of erythrocytes, is a dynamic process finely
regulated by cytokines, hormones, and growth factors at transcriptional and
translational levels134, 136. Since erythrocytes, the most abundant cell type in the
circulation, is the major source of oxygen to local tissues, erythropoiesis is
stimulated under conditions of insufficient oxygen availability such as high altitude,
blood loss, infection, and anemia. This so-called stress erythropoiesis process is
defined by an expansion of the erythroid progenitor pool, associated with
reticulocytosis and splenomegaly. Thus, stress erythropoiesis is an important
stress adaptive response for survival. Although stress erythropoiesis has been
linked with increased metabolic requirements, the molecular basis promoting
metabolic reprogramming to enhance energy metabolism to support stress
erythropoiesis remains unclear. Our recent studies identify a decisive role of
elevated adenosine signaling in stress erythropoiesis. Mouse genetic studies
showed that activation of adenosine signaling via erythroid ADORA2B promotes
the commitment of erythroid both in spleen and bone marrow and in this way
contributes to hypoxia-induced stress erythropoiesis independent of plasma Epo.
Using unbiased high-throughput metabolic profiling coupled with microarray, we
identified that erythroid ADORA2B contributes to an overall hypoxia metabolic
reprogramming with substantially increased glycolysis, TCA cycle intermediates
are produced by erythroid progenitors in mice. In addition, follow-up mouse anemia
in vivo and mouse HSC ex-vivo studies showed that erythroid ADORA2B-HIF1 is
critical for erythroid commitment under stress condition. Thus, our studies identify
adenosine ADORA2B is a previously unrecognized purinergic signaling underlying
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hypoxia-induced erythropoiesis by regulation of metabolic reprogramming in
erythroid progenitors, and likely discover new therapeutic targets to counteract
hypoxia-induced injury by induction of erythrocyte number.
All living cells require energy for survival proliferation and differentiation to
adapt to physiological and pathological stress conditions by metabolizing three
major nutrients including glucose, glutamine and fatty acids. Changes in nutrient
utilization and metabolism is termed "metabolic reprogramming" in response to any
stimuli137.
Although adenosine, HIF-1 is induced by stress conditions such as
hypoxia138, the role and interaction of these hypoxic sensors in stress
erythropoiesis were previously unrecognized. By using innovative unbiased high
throughput metabolomics, coupled with our flux analysis of isotopically labeled
metabolites, multiple genetic mouse models, we show for the first time that
elevated adenosine signaling-mediated erythroid ADORA2B-HIF-1 activation
contributes to stress erythropoiesis. Our studies reported here allow us to identify
a new pathway of adenosine signaling via erythroid ADORA2B-HIF-1 regulating
erythroid commitment, and subsequently contributing stress erythropoiesis by
regulation of metabolic reprogramming. Our findings are novel and significant
which identify multiple new therapeutic targets to regulate HSC lineage
commitment, and thereby benefits for normal individuals at stress conditions and
patients with hematology disorders.
Adenosine is ubiquitously existed in almost all of the cell type in our bodies,
which is critical intermediate metabolite of nucleic acids as a building block. As a
key signaling molecule, adenosine orchestrates the cellular response to hypoxia,
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energy depletion, and stress challenge by activation of its G protein-coupled
receptor (GPCR) on multiple cell types. Our results showed that ablation of
erythroid ADORA2B in mice results in impaired erythropoiesis in response to stress,
similar to CD73-deficient mice, indicating that adenosine-activated erythroid
signaling pathway reveals new dimensions of the importance of adenosine
signaling in adaptation to stress condition.
Although HIF-1 is induced by stress condition, and play an important role in
regulation of metabolic reprogramming138, the role of HIF-1 in stress
erythropoiesis is not well characterized. HIF-1 increases Adora2b gene
expression under stress condition. More recently studies showed that ADORA2B
feedback induces Hif-1 gene expression in other cellular systems94. By
generating genetically modified mice with specific knockout in erythroid lineage,
we showed that adenosine signaling via erythroid ADORA2B coupled with HIF-1
reciprocal upregulation induces metabolic reprogramming, regulates erythroid
commitment, and therefore promotes erythropoiesis in response to stress condition.
Taken together, our studies reveal novel pathway and molecules linking
purinergic signaling with erythroid metabolic reprogramming and HIF-1 targeted
gene expression, which regulate erythroid commitment, and subsequently
contributing stress erythropoiesis. The significance of our studies could be
enormous since our results provide new insight to stress erythropoiesis for
identification of innovative therapeutic approaches to promote erythropoiesis.
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Chapter 4
4 Conclusion and future direction
4.1 Conclusion
Hypoxia is a condition in which the whole body or local organ and tissue is
starved of sufficient oxygen supply. Hypoxia is a particularly dangerous condition
for both normal individuals under high altitude hypoxia and patients with basic
cardiovascular, respiratory and hemolytic diseases89,

90.

Due to a lack of

fundamental understanding of the molecular mechanisms underlying adaptation to
hypoxia, current strategies to counteract hypoxia are limited. As the only cell-type
responsible for delivering O2 to peripheral tissues in our body, mature RBCs quickly
respond to hypoxia by increasing its O2 delivery ability. Although it has been long
speculated that RBC play an important adaptive role in response to hypoxia,
specific molecules and signaling pathways involved in mature RBC "metabolic
reprogramming" for rapid response to increase O2 delivery to counteract hypoxiainduced tissue damage and prevent disease progression remain elusive.
By conducting pilot high altitude human studies, we observed that plasma
adenosine concentration and sCD73 activity increased along with erythrocyte 2,3BPG levels and O2 releasing capacity in humans at high altitude. Follow-up mouse
genetic studies demonstrated for the first time that CD73-dependent elevation of
plasma adenosine signaling via erythrocyte specific ADORA2B is a key
mechanism for hypoxia adaptation by inducing 2,3-BPG production and triggering
O2 release to counteract multiple tissue severe hypoxia. Mechanistically, we
revealed that AMPK is a key enzyme that functions downstream of ADORA2B
signaling and contributes to hypoxia-induced 2,3-BPG production and subsequent
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O2 release from erythrocytes in mice and humans. Overall, both human and mouse
studies reported here provide strong evidence that CD73-dependent elevation of
plasma adenosine, signaling via ADORA2B on erythrocytes, plays a beneficial role
in preventing altitude-mediated tissue hypoxia by inducing 2,3-BPG production and
triggering O2 release in a AMPK-dependent manner (Fig. 6g). Thus, our findings
reveal novel therapeutic targets to protect against tissue hypoxia and provide a
strong foundation for future clinical trials. Our studies here addresses the challenge
of identifying novel approaches for the safe and effective treatment to counteract
acute hypoxia, a dangerous condition causing multiple tissue damage, dysfunction
and sudden death. Our ultimate goal is to transform the results of our innovative
metabolomic screen to new mechanism-based therapeutics to reduce hypoxiainduced tissue damage and dysfunction by targeting erythrocyte metabolites and
their signaling pathways newly identified by our studies. Our research will likely
provide new insight to our understanding of the molecular mechanisms of
improving O2 delivery from erythrocytes in any condition facing hypoxia. It may
reduce morbidity and mortality for the billions individuals worldwide who suffer from
hypoxia, which is beneficial for the health and well-being of billions of individuals
with hypoxia.
Since it is impossible to analyze tissue damage at different time points in
humans, we plan to conduct preclinical studies to address these questions in future
direction. These studies are expected to provide evidence of the therapeutic effects
of BAY-60-5683 (ADORA2B agonist), AICAR (AMPK agonist) and dipyridamole
(adenosine booster) to promote O2 release in human high altitude studies and
reduce hypoxia. Furthermore, if we validate our mouse studies showing that
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elevated adenosine-mediated activation of erythrocyte AMPK as we hypothesize,
enhancing circulating adenosine levels by dipyridamole, ADORA2B by BAY-605683 and activation of AMPK by AICAR may represent novel effective therapeutic
approaches for the treatment of hypoxia. We expect our human translational
studies to provide a strong foundation of evidence to move forward quickly to
conduct clinical trials in humans to prevent and treat hypoxia conditions including
acute mountain sickness and many diseases associated with hypoxia.
Change of O2 release capacity of erythrocytes is not the only adaptive
mechanism in response to stress condition that contributes to enhancement of O2
availability. Erythropoiesis, the production of erythrocyte number, is also one of the
well-known adaptive mechanism in response to stress condition 130. Although
adenosine is well known to be induced by hypoxia, the role and molecular basis of
adenosine signaling in stress erythropoiesis were not previously recognized.
Similarly, HIF-1 is known to be induced by hypoxia138. However, the role of HIF1 in hypoxia-induced stress erythropoiesis is not well characterized due to lack of
genetically modified mice with specific knockouts of HIF-1 in erythroid progenitors.
With proof-of-principle novel genetic tools, our findings that elevated adenosine
signaling through ADORA2B coupled with HIF-1 reciprocal upregulation to induce
hypoxic metabolic reprogramming to promote new RBC production to offset
hypoxia and protect from hypoxic tissue damage. Using multiple innovative
techniques including high throughput metabolomics analysis and mRNA microarray sequencing identify purinergic signaling with erythroid hypoxic metabolic
reprogramming, coupled with HIF-1 targeted gene expression, contributing to
erythropoiesis by regulation of erythroid commitment.
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Overall, our newly discovered molecular mechanisms underlying purinergic
signaling with HIF-1 in erythroid metabolic modulation identified by the study here
will add a new chapter to erythroid physiology and pathology and open up new
therapeutic possibilities to counter tissue hypoxia at all conditions.
Thus, our findings that elevated adenosine signaling through erythroid ADORA2BHIF-1 interactively feed forward to induce erythroid progenitor hypoxia metabolic
reprogramming and stress erythropoiesis is extremely new and novel. Of
significance, our studies identify new signaling pathway regulating erythroid
metabolic modulation by a sophisticated and collaborative puringeric signaling
network linked with HIF-1 to promote erythroid commitment under
erythropoiesis.
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4.2 Future direction for chapter 2.
Our current studies showed that the activation of ADORA2B signaling is
essential to stimulate 2,3-BPG production and promote O2 release from RBCs to
counteract tissue

damage in mice in response to acute hypoxic exposure.

Recently, our preliminary studies showing for the first time that genetic deletion of
erythrocyte ADORA2B significantly reduced Ang II-induced RBC 2,3-BPG and P50
and in turn resulted in more kidney tissue damage featured with proteinuria
compared to Ang II-infused WT mice. Thus, our study demonstrated the broad
beneficial role of RBC ADORA2B-mediated elevated 2,3-BPG levels and O2
delivery Ang II-induced kidney injury model. Additionally, we have recently made
significant progress showing that AMPK functions downstream of ADORA2B and
that AMPK activation by AICAR is sufficient to induce 2,3-BPG production and
enhanced O2 release in cultured human RBCs. These findings immediately
suggest that promoting ADORA2B and AMPK activation are new therapeutic
strategies to counteract hypoxia. Therefore, our finding of the beneficial role of
elevated adenosine signaling via RBC ADOAR2B coupled with AMPK activation to
promote O2 delivery highlights this signaling pathway as a therapeutic target to
counteract tissue hypoxia.
Because of the importance of adenosine-mediated erythrocyte ADORA2B
activation in counteracting tissue hypoxia in both hypoxia exposed and Ang IIinfused models, we anticipate that these two drugs will reduce hypoxia or Ang IIinduced tissue damage and dysfunction by rapidly inducing circulating adenosine,
2,3-BPG and O2 release in these two independent models.
The beneficial role of RBC ADORA2B-mediated AMPK signaling in
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physiological and pathological hypoxia-induced tissue damage had not been
recognized until we conducted metabolomic screening and mouse genetic
studies139. Because hypoxia is frequently associated with CVD, enhancing O2
release by these two new mechanistic treatments may also improve cardiovascular
function by reducing tissue damage. Thus, we believe our mechanistic discoveries
regarding erythrocyte ADOAR2B- mediated AMPK activation and subsequent O 2
release is highly innovative and extremely significant since these findings have
added a significant new chapter to erythrocyte physiology and open up multiple
new therapeutic opportunities for the treatment of acute high altitude sickness and
hypoxia-related diseases.
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4.3 Future direction for chapter 3.
To address what are the key enzymes and gene expression mediated by
ADORA2B-HIF-1

signaling

network

contributing

to

hypoxia

metabolic

reprogramming and supporting stress erythropoiesis, we will take advantage of
multiple novel mouse genetic tools coupled with several innovative and cutting
edge metabolic analytical techniques developed by us in recent years as below.
RNA deep sequencing: To determine if HIF-1 as a key hypoxic transcription
factor regulates other genes besides Adora2b, we will use robust RNA deep
sequencing

to

compare

the

overall

changes

of

RNA

expression

in

CD71highTer119high progenitors isolated from BM and spleen of EpoR-Cre+,
Adora2bf/fEpoR-Cre+, HIF-1f/fEpoR-Cre+, mice in response to hypoxia at different
time points up to 72 hours. We will further use RT-PCR to validate and compare
the gene expression levels of CD71highTer119high progenitors isolated from BM and
spleens of EpoR-Cre+, Adora2bf/fEpoR-Cre+, HIF-1f/fEpoR-Cre+ mice under
normoxia and hypoxia conditions at different time points up to 72 hours with a
special focus on multiple known HIF-1-targeted genes including Glut1/4, pyruvate
kinase and pyruvate dehydrogenase kinase.
Human in vitro studies: To validate our findings in mouse, after expansion
human CD34+ BMCs, we will further culture the cells in erythroid differentiation
medium with or without ADORA2B agonist (BAY-60-5683) or HIF-1 stabilizer
(DMOG).
In addition, we will further validate all of those identified HIF-1-targeted
genes and metabolic changes from mice in humans by using the treated human
137

CD34+ HSC cultures above. Specifically, we will compare the effects of BAY-605683 or DMOG treatment on AMPK-mediated specific phosphorylation of the
identified enzymes, gene expression and metabolites in those cells.
The proposed studies with multidisciplinary approaches have a high likelihood
to identify multiple new pathways regulating erythroid metabolic modulation by a
sophisticated and collaborative puringeric signaling network linked with HIF-1 to
promote erythroid commitment under stress erythropoiesis, and set up foundation
to future clinical trials and provide therapeutic strategy to improve effective and
sufficient erythropoiesis in various conditions.
Thus, my dissertation research has identified that adenosine signaling
functions as novel a molecular mechanism involved in the regulation of erythrocyte
O2 release capacity and O2 delivery capacity, providing therapeutic possibilities to
enhance O2 availability and prevent stress-induced tissue damage and
inflammation.
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